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RNA silencing, which is triggered by small RNAs, is a powerful gene 
expression regulation mechanism and results in sequence specific inhibition of gene 
expression by translational repression and/or mRNA degradation. Small interfering 
RNAs (siRNAs) and microRNAs (miRNAs) are processed by RNase III enzymes and 
subsequently loaded into Argonaute (AGO) proteins, a key component of the RNA 
induced silencing complex (RISC). RISC is a multi-protein complex that incorporates 
Argonautes, the bound small RNA, and other AGOs interacting proteins. Among 
these RISC components, kiaa1093 is a poorly understood protein. In this thesis 
(chapter 3), we solve the crystal structure of kiaa1093 C-terminal RNA recognition 
motif (RRM) and establish the physical association between TRBP and kiaa1093 via 
its C-terminal RRM domain in vitro. Compared with canonical RRMs, kiaa1093 
RRM is composed of an additional C-terminal α helix, which is important to bridge 
TRBP and kiaa1093’s interaction. Remarkably, kiaa1093 RRM enhance TRBP’s 
RNA affinity. Therefore we hypothesize that kiaa1093 may function as a scaffold 
protein to strengthen TRBP/siRNA interaction and help TRBP to recruits Dicer 
complex to Argonaute 2 for gene silencing events. Argonaute proteins in RISC are 
also potential targets for viral suppressors to suppress the host RNA silencing. For 
example, CMV 2b, encoded by cucumovirus, is targeting AGO1 in Arabidopsis. 
However, its homolog Tomato aspermy virus (TAV2b), which is also encoded by 
cucumovirus, may suppress host RNA silencing through binding small RNAs on the 
basis of our work. In chapter 4, we report the crystal complex structure of TAV2b 
bound to a 19 bp siRNA duplex. We observe that TAV2b adopts an all α-helix 




preference mode, which is different from the binding modes adopted by either Tomato 
bushy stunt virus (TBSV)/Carnation Italian ringspot virus (CIRV) p19 or flockhouse 
virus (FHV) B2.   




Chapter One: Literature Review 
Part І: A Structural Perspective of the Protein–RNA 




RNA silencing regulated by small RNAs, including siRNAs, miRNAs, and 
piRNAs, results in sequence specific inhibition of gene expression by translational 
repression and/or mRNA degradation, which acts as an ancient cell defense system 
against such molecular parasites as transgenes, viruses, and transposons. In response, 
many viruses encode suppressors to suppress RNA silencing. However, the striking 
sequence diversity of viral suppressors suggests that different viral suppressors could 
target various components of the RNA silencing machinery at different steps in divers 
suppressing modes. Significant progresses have been made in this field within the past 
5 years on the basis of structural information derived from RNase III family proteins, 
Dicer fragments and homologs, Argonaute homologs and viral suppressors. This 
chapter will review the current understanding of the structural components in RNA 
silencing pathway and the structural mechanisms of RNA silencing suppression. 
1. Introduction  
RNA silencing, an RNA-based gene regulatory mechanism, is regarded as an 
intrinsic host defensive strategy for a wide range of eukaryotic organisms ranging 
from fission yeast, plants, insects, to mammals. The RNA silencing like phenotype 




Wingard [1, 2]. It was reported that only the initially infected leaves (lower) rather 
than the non-infected leaves (upper) show disease related symptoms, which suggests 
that tobacco has developed an antiviral defense mechanism to counter TRSV infection 
[1, 2]. Despite of the early discovery, research on RNA silencing has been boomed up 
recently right after the discovery of double stranded RNA (dsRNA) as a trigger to 
activate RNA silencing [3]. RNA silencing is an evolutionarily conserved process 
comprising a set of following core reactions. Firstly, Dicer-like RNase III enzymes 
recognize and process long complementary dsRNA into 21-24 base pairs (bp) siRNA 
[4]. Subsequently, the siRNA duplex is loaded into RISC, which is ATP-depended 
[5]. The passenger strand of siRNA duplex is degraded by RISC, whereas the guide 
strand is bound to RISC and directs the target mRNA degradation based on the degree 
of the complementarities between the guide strand and mRNAs [6, 7, 8, 9].  
RNA silencing can be triggered by virus infection, leading to specific recognition 
and degradation of the invading virus RNAs [10, 11, 12]. In response to host defense, 
viruses have developed a wide range of mechanisms to overcome RNA-silencing, 
providing an example of “evolutionary arms race between hosts and parasites” [10, 
13]. Therefore, elucidating the mechanisms of initiation and suppression of RNA 
silencing triggered by virus infection could provide important insights into the 
regulation of gene silencing and the cross-talk between hosts and pathogens. This 
chapter of literature review will present current progress on the understanding of RNA 
silencing and especially highlight the structural principles determining the protein–
RNA recognition events along the RNA silencing pathways and the suppression 




2. Key components in RNA silencing pathway 
2.1. Triggers for RNA silencing 
Small dsRNAs harboring three distinct features (21-30 nucleotides (nt) in length; 
5’-phosphate; and 3’-2 nt overhangs.) serve as the triggers to activate RNA silencing 
pathway. These small dsRNAs are mainly grouped into three classes: small interfering 
RNAs (siRNAs), microRNAs (miRNAs), and Piwi-associated interfering RNAs 
(piRNAs).  
2.1.1. siRNAs 
siRNAs are processed from long dsRNA precursors by Dicer or Dicer-like RNase 
III enzymes (Figure. 1-1). They are produced from transcribed dsRNAs (endogenous 
siRNAs), or introduced by chemically synthesized dsRNAs (exogenous siRNAs), or 
resulted from virus infection [10]. siRNA bound RISCs are crucial to defend host 
genomes against transgenes, transposons and viral invasion. Endogenous plant 
siRNAs are either generated directly from transcription or derived from inverted 
repeats of transgenes or transposons [13]. In plants, siRNAs are either readily 
identified from virus infected cells or transgenic plants. There are two groups of 
siRNAs detected in plants based on size: 21-22 nt specie is reported to guide RISC for 
viral mRNA degradation, whereas 24 nt specie is considered to direct DNA and 
histone methylation [14, 15]. 
2.1.2. miRNAs 
miRNAs are on average of 20 to 23 nt in length and usually have a uridine at their 




















Figure 1-1. Schematic overview of siRNA pathway.  
A. siRNA pathway in human. Long dsRNA is cleaved by dicer and subsequently loaded into 
siRISC with AGO2 as the catalytic component. Many Argonaute interacting proteins play 
important functional roles for AGO2-mediated mRNA cleavage. Some animal viruses encode 
viral suppressors, such as B2 and NS1A, targeting both long dsRNA and siRNA duplex to 
suppress RNA silencing.  
B. siRNA pathway in Arabidopsis. DCL4 is the primary ‘dicing unit’ for dsRNA processing. 
When DCL4 is suppressed, DCL2 plays a backup role for dicing. AGO1 is the ‘slicing unit’ 
for mRNA cleavage. In Arabidopsis, RDR6/SDE3 plays the unique roles to amplify the 
aberrant RNA into dsRNA, which is distinct to siRNA pathways in human and Drosophila. 
Plant viruses encode numerous viral suppressors targeting at different steps of siRNA 
pathway to suppress RNA silencing. For example, HcPro targets the long dsRNA; P19 targets 
the siRNA duplex, whereas CMV2b and P0 target AGO1. 
C. siRNA pathway in Drosophila. Dcr-2 and AGO2 are the key catalytic functional 
components involved in this pathway. Dcr-2/R2D2 work collaborately to serve as a 





sequentially in nucleus and cytoplasm (Figure. 1-2A). In nucleus, Drosha processes 
the pri-miRNA into around 70 nt long pre-miRNA with stem-loop architecture [17],   
which is subsequently transported to cytoplasm in a GTP-dependent manner by 
Exportin 5 [18]. After transported into cytoplasm, pre-miRNA is further processed by 
Dicer into the miRNA duplex with 3’-2 nt overhangs. In plants, pri-miRNA is 
processed to pre-miRNA then miRNA duplex by Dicer within nucleus (Figure. 1-2B) 
[19]. Moreover, methyl group is deposited to the 2’-OH of 3’ terminal nucleotide in 
plant miRNA [20], whereas no methylation modification is observed for animal 
miRNA [21]. miRNA bound miRNPs (effector complexes containing miRNAs) not 
only target mRNAs for degradation or translation inhibition, but also induce mRNA 
destruction via deadenylation and decapping processes, and thus  regulate the gene 
expression [22, 23]. 
Besides cellular miRNAs, viruses also encode a series of viral miRNAs 
(exampled by herpesviruses) [24]. Virus usurps the host miRNA processing 
machinery to process viral miRNA. After the host is infected by the virus, the viral 
genome is transcribed and processed into viral RNA with pri-miRNA like architecture 
by host processing machinery. Pre-miRNA is subsequently processed into viral 
miRNA, which is loaded into host RISC. Therefore, the transcription and processing 
mechanisms between viral miRNA and cellular miRNA are almost identical. The 
functions of viral miRNA might be involved in the attenuation of the host immune 
response or regulate viral life cycle by regulating its own viral protein expression [25, 






















Figure 1-2. Schematic overview of miRNA pathway.  
A. miRNA pathway in human. Pri-miRNA is processed into pre-miRNA by Drosha/DGCR8 
complex in nucleus. Pri-miRNA is subsequently transported into cytoplasm by Exportin-
5/Ran complex. Pre-miRNA is further processed into miRNA/miRNA* duplex by Dicer and 
subsequently loaded into the miRNP. The miRNA strand bound to miRNP targets mRNA for 
mRNA cleavage D or induces its degradation through deadenylation and recapping processes 
E, or targets active polyribosomes to repress the translation F. (Abbreviation: m7G, m7G-cap; 
AAAA, polyA-tail; 40S and 60S, active ribosomal subunits).  
B. miRNA pathway in Arabidopsis is quite distinct from that of human Drosophila system. 
The processing of miRNA/miRNA* duplex is achieved by a single processing machinery 
comprising DCL1/HYL1/SERRATE in nucleus. miRNA duplex is transported into cytoplasm 
by Exportin-5/Hasty instead.  
C miRNA pathway in Drosophila, which is similar to human miRNA pathway. Loqs and 






piRNAs are around 28-33 nt long which are discovered in Drosophila, worms 
and mammals. piRNA has a preference for a uridine at its 5’-end and 2’-O-methylated 
at its 3’-end. Unlike miRNAs and siRNAs, piRNAs are not processed by RNase III 
enzymes [27]. In Drosophila, piRNA generation follows a so called “ping-pong” 
model with two kinds of piRNAs [28]: one is genetically encoded primary piRNAs 
and the other is adaptive secondary piRNAs. Primary piRNAs are generated from 
piRNA clusters that contain the highest density of transposon-related sequences. 
Primary piRNAs interact with and direct Piwi proteins to target mRNAs. As a result, 
the mRNAs are cleaved, which, meanwhile, promote the generation of secondary 
piRNAs derived from the mRNAs [28]. Although some reports indicated that piRNA 
might be involved in spermatogenesis and might play a role in silencing of 
transposable elements [29, 30, 31, 32, 33], the targets and the exact biological 
functions of mammalian piRNAs are still largely unknown. 
2.2. Dicers 
2.2.1. Roles of Dicers in processing small RNAs 
There are multiple Dicers or Dicer-like proteins that function differently 
within RNA silencing pathway. Different Dicer-like proteins work either 
independently or redundantly or even cooperatively to fulfill a wide range of 
functions in context with RNA silencing. In Drosophila, miRNAs are generated by 
Dicer-1 (Dcr1), whereas siRNA (including viRNA) are generated by Dicer-2 (Dcr2) 




one Dicer responsible for production of both siRNAs and miRNAs. In Arabidopsis 
thaliana, there are 4 Dicer-like proteins, namely DCL1-4. DCL1 plays the role in 
miRNA processing (Figure. 1-2B), whereas DCL2-4 proteins generate siRNAs with 
distinct sizes (Figure. 1-1B). DCL2 processes long dsRNAs into 22 bp, whereas 
DCL3 and DCL4 produce 24 bp siRNAs and 21bp siRNAs, respectively [14, 37, 38, 
39, 40].  
2.2.2. Roles of Dicers in processing Virus-derived small interfering 
RNAs (viRNAs)  
Both the long dsRNA replication intermediates and the imperfect RNA 
hairpins derived from viral RNAs are processed into dsRNAs by RNase III enzymes 
to activate RNA silencing. In Drosophila, Dcr-2/R2D2 heterodimer is responsible for 
loading viRNA into AGO2 complexes, but not for dicing [41]. In Arabidopsis, DCL4 
is the primary Dicer responsible for viral RNA processing [40, 42, 43], whereas 
DCL2 functions as the backup of DCL4 [42]. Interestingly, four Arabidopsis DCLs 
seem to work as a team to fight against DNA virus infection [11].  
2.2.3. Ribonuclease III enzymes partners 
Many dsRNA binding proteins have been identified as Dicer partners function 
in facilitating small RNA processing, strand selection and RISC assembly [44, 45, 
46]. (Dicers’ partners such as TRBP, R2D2, PACT, and R3D1 which also associate 
with AGOs will be discussed in “RISC loading complex” part). In human, DGCR8 
binds more favorably to the ssRNA-dsRNA junction and serves as a molecular ruler 
to recruit Drosha for the precise cleavage of pri-miRNA around 11 bp away from the 
junction [44] (Figure. 1-2A). A recent crystal structure reported that the human 




tandem primarily recognizes the pri-miRNAs substrates and recruits Drosha to 
process pri-miRNAs into pre-miRNAs. Crystal structure of DGCR8 core shows a 
highly compact structure with two dsRBDs packed against each other. Surprisingly, 
DGCR8 core is not able to recognize the ssRNA-dsRNA junction, which suggests that 
other portions of DGCR8 may play the role to anchor the junction [47]. The homolog 
of DGCR8 in plant is HYL1, which was reported to play significant roles in 
recognizing certain structural features of pri-miRNAs and in recruiting DCL1 to 
process pri-miRNAs into pre-miRNAs (Figure. 1-2B) [48, 49]. 
2.2.4. The structural understanding of Ribonuclease III family enzymes 
The RNase-III type enzymes are responsible for both miRNAs and siRNAs 
processing. Here we discuss the current structural understanding of these proteins and 
the possible processing mechanism. There are three classes of Ribonuclease III family 
enzymes with increasing molecular weight and complexity of the polypeptide chain. 
All these Ribonuclease III family enzymes harbor one or two RNase III domains in 
tandem, which are conserved in bacteria, bacteriophages, and fungi (Figure. 1-3A).   
Class 1 RNase III enzymes are simplest and only discovered in bacteria. 
Members in this class contain a single N-terminal RNase III domain and a single C-
terminal dsRBD. The dimeric arrangement of each RNaes III domain enables class 1 
proteins to form a “catalytic valley” [50] targeting one strand of RNA substrate for 
hydrolysis and yield the cleavage product with the unique 3’- 2nt overhangs [51]. A 
typical member in this class is Aquifex aeolicus RNase III protein, which provides 
detailed structural information on the ‘one processing center’ mechanism adopted by 
all RNase III family members (Figure. 1-3B) [50]. The crystal structure of an inactive 




indicated that the dimeric dsRBDs are mainly responsible for dsRNA recognition and 
binding, whereas the dimeric RNase III domains form the catalytic valley with two 
magnesium ions at the active site [52]. The side chains from dsRBDs recognize the 
minor groove of the bound dsRNA whereas the side chains from RNase III domains 
interact with non-bridging phosphate oxygen and 2’-hydroxyl ribose oxygen of the 
dsRNA backbone [50].   
Class 2 RNase III enzymes are more complicated and contain two RNase III 
domains and one dsRBD at C-termini, as well as uncharacterized structural motif at 
N-termini. The representative protein in class 2 is Drosha, which is responsible for 
processing pri-miRNA into pre-miRNA hairpin. Drosha contains an N terminal 
proline-rich region, two RNase III domains in tandem and a dsRBD. Drosha 
recognizes and processes pri-miRNA with the assistance of DGCR8 in the “ssRNA-
dsRNA Junction Anchoring” Model. DGCR8 recognizes the stem-ssRNA junction 
portion of pri-miRNA and recruits Drosha to cleave the pri-miRNA around 11 bp 
away from the stem-ssRNA junction [44]. 
Class 3 RNase III enzymes are the most complicated and contain two 
ribonuclease domains, one or two dsRBD at C-termini, an N-terminal DExD/H-box 
helicase domain, a small domain with unknown function (DUF283), and a PAZ 
domain. The characterized one in this family is Dicer. The recent solved crystal 
structure of Dicer-like protein from human parasite Giardia intestinalis provides 
detailed structural information that is helpful to understand the catalytic mechanism of 
Dicer mediated small RNA maturation (Figure. 1-3C) [52]. Giardia Dicer represents a 
truncated version of the typical Dicer proteins, which contains only a PAZ domain 




DExD/H-box helicase, DUF283 and C-terminal dsRBDs domains [52]. In this 
structure, the domain arrangement of the two tandem RNase III (IIIa and IIIb) 
domains is just like that of Aquifex aeolicus with the single catalytic center formed by 
the intramolecular dimer between RNase IIIa and Rnase IIIb. This structural finding 
further suggests that ‘one processing center’ mechanism is probably conserved for all 
Dicer-like proteins, including Drosha. Remarkably, Giardia Dicer structure adopts a 
hatchet-like architecture with the RNase III domains resembling the “blade”, and the 
PAZ domain together with one unique long α helix, which is connecting the PAZ 
domain and the RNase III domains, resembling the “handle” [52]. Since the PAZ 
domain is proposed to recognize the 3’- 2nt overhangs of dsRNAs [53, 54, 55, 56], 
this unique connecting α helix could function as a molecular ruler to measure the 
distance from the dsRNA end (recognized by PAZ domain) to the cleavage site 
(provided by RNase III domains) [52]. The structural similarity between bacterial 
RNase III proteins and mammalian Dicer proteins is further confirmed by the recent 
crystal structure of a Dicer fragment from mouse [57].  Although this Dicer fragment 
contains only the RNase IIIb and dsRBD, it forms a symmetric homodimer similar to 
Aquifex aeolicus RNase III and is capable of dsRNA cleavage [50, 57]. The structural 
information for Dicer helicase domain and DUF283 is still not available. However, 
DUF283 is proposed to have a double stranded RNA binding fold [58]. The functions 
of helicase domains from different Dicer proteins in various organisms seem different. 
For example, Giardia Dicer is capable to cleave dsRNA substrates in vitro although it 
lacks helicase domain [52]. Human Dicer’s activity is ATP independent in vitro [59, 
60], whereas Drosophila Dicer’s activity is increased with the addition of ATP [61]. 
However, the mutations in fission yeast Dicer helicase domain disrupt the dicing 








Figure 1-3. Domain arrangement of RNase III type enzymes and their structures.  
A. Schematic representation of domain arrangement of RNase III type enzymes.  
B. Cartoon representation of crystal structure of the catalytic inactive Aquifex aeolicus RNase 
III bound to dsRNA. The catalytic key residue in the active pocket (D44N) is highlighted in 
red and the divalent metal ions are highlighted as green balls. 
C. Cartoon representation of crystal structure of Giardia Dicer. The catalytic key residues in 
the active pocket (D340 and D653) are highlighted in red and the divalent metal ions are 




display defects in female fertility and ovule development [63]. Recent work on human 
Dicer indicated that human helicase domain plays an important role to autoinhibit 
human Dicer’s function in vitro [64]. Although RNA helicase plays multiple roles for  
RNA transcription, pre-mRNA splicing and protein translation, it remains unknown 
how the RNA helicase domain of Dicer is involved in the process of dsRNA cleavage. 
The structural work of Dicer helicase in the context of Dicer-mediated complexes 
may answer some of these questions. 
2.3. Argonautes  
Argonautes are one of the key functional components of RISC and play critical 
role for RISC-mediated RNA silencing in fission yeast, fungi, plants, worms, flies and 
mammals [65]. Argonautes together with the bound small RNA are composed of the 
minimal functional units of RISC [66, 67].  
2.3.1. Minimal RISC 
Both human and Drosophila Argonautes are reported to take up the siRNA 
duplex, degrade the passenger strand, bind to the guide strand to form the functional 
minimal RISC and initiate sequence specific cleavage of the target mRNAs [7, 8, 66, 
68]. Argonautes are discovered in a wide range of organisms but the numbers in the 
genome vary in different species. In human, there are eight Argonaute-like proteins 
including four Argonaute family proteins and four Piwi family proteins, whereas in C. 
elegans, there are around 27 Argonaute-like proteins [69]. In Arabidopsis, there are 
10 Argonaute proteins. Interestingly, these Argonautes prefer to bind to specific small 
RNAs with different 5’ terminal nucleotide. For example, Arabidopsis AGO2 and 




preferentially binds to miRNAs with 5’ terminal uridine, whereas AGO5 
preferentially binds to small RNAs with 5’ terminal cytosine [70]. Remarkably, 
changing the 5’ terminal nucleotide of a given miRNA will redirect this miRNA to 
load into its favorite AGO and correspondingly changes its biological function [70]. 
In addition, Arabidopsis AGO1 was also identified as the catalytic functional 
component of viRISC [71]. The structural basis for the specific 5’-termial nucleotide 
recognition by different Argonautes is still unknown due to the lack of the structural 
information of any eukaryotic Argonaute. The current structural information deduced 
from the A. fulgidus MID/PIWI structure is not informative at this point because of 
the low sequence similarity between the MID domain of A. fulgidus MID/PIWI 
protein and those of eukaryotic Argonaute proteins (we will discuss the specific 5’-
termial nucleotide recognition pocket later). 
2.3.2. Argonautes partners 
Argnaute proteins together with their partner proteins fulfill the RNA silencing 
functions in vivo. The knockdown of Argonaute partner proteins significantly disables 
the Argonaute function in vivo [72, 73]. The biochemical analysis of human AGO1-
and AGO2-containing protein complexes indicated that most of human AGO1 and 
AGO2’s partner proteins are RNA binding proteins [74]. The interactions between 
AGOs and their partner proteins can be either direct protein-protein interaction or 
RNA-mediated interaction. Human Dicer is also an Argonaute partners [75], which 
directly binds to PIWI box of human AGO2 [76]. The direct interaction between 
Dicer and AGO indicates that Dicer plays important roles both in small RNA 
maturation and in loading RNA into Argonautes. Several other important AGO2 




TNRC6B/KIAA1093 [77], RMB4 [74], RHA [78], and IMP8 [73], are revealed 
recently by further affinity pull down experiments. Interestingly, TNRC6B is the 
paralog of GW182/TNRC6A, the marker of P bodies (processing bodies) [79], which 
is also one of the Argonautes’ partners. GW182 family proteins are essential for 
miRNA-mediated gene silencing. They interact with AGOs and co-localized at P 
bodies [77, 80, 81]. In Drosophila, GW182 is reported to directly interact with PIWI 
domain of AGO1 [77, 80, 82, 84]. Detailed sequence analysis and domain mapping of 
different Argonaute partners revealed that a linear repetitive Gly-Trp (GW) or Trp-
Gly (WG) sequence motif directly binds to AGO PIWI domain [83]. This motif, 
termed as “AGO hook”, is conserved from yeast AGO partner (Tas3) to human AGO 
partner (TNRC6B/KIAA1093) [83]. Structural modeling indicated that the AGO hook 
binding pocket within AGO protein is next to and probably partially overlap with the 
5’-end of siRNA recognition pocket (Figure. 1-4F). Further functional analysis 
indicated that two conserved phenylalanine residues within the PIWI domain of both 
D. melanogaster AGO and mammalian AGO are essential for the interaction with 
GW182 as well as AGO-mediated RNA silencing activity [84].  
2.3.3. P bodies 
P bodies are small granular structures in cytoplasm of eukaryotic cells, which are 
considered as loci for mRNA decay and are correspondingly involved in mRNA 
surveillance, translational control and RNA-mediated silencing [79, 81, 85]. Although 
several lines of evidence have established the link between P bodies and RNA 
silencing, P bodies are not the essential factor for the occurrence of RNA silencing. 





Besides GW182, decapping complex (consisting of DCP1 and DCP2) also 
localizes at P bodies, which is considered for decapping and degradation of 
bulkmRNAs in the 5’ to 3’direction in eukaryotic cells. This DCP1/DCP2 decapping 
complex is also required for the miRNA pathway [87]. The complex structure of 
DCP1/DCP2 reveals that DCP2 exists in both open and closed conformations, which 
suggests that change between these open and closed conformations might control 
decapping [89]. 
2.3.4. RISC loading complex 
Small RNA duplexes processed by RNase III family enzymes (Dicers or Dicer-
like proteins) are loaded into Argonautes by RISC loading complex. Although many 
RNA binding proteins have been identified as Argonautes’ partners for proper RISC-
mediated activity [74], only a small fraction of these proteins have been functionally 
characterized [73, 74, 77, 78, 90]. Among these AGO partners, some are found in 
RISC-loading complex (RLC). In Drosophila, RLC contains siRNA duplex, the 
dsRNA binding protein R2D2, Dicer-2 (Dcr-2), and probably several other 
unidentified proteins [45]. R2D2 functions as a protein sensor to measure the 
thermodynamic stability of the bound siRNA duplex. R2D2 binds to the siRNA end 
with the greatest double-stranded character, whereas Dcr-2 binds to the siRNA end 
with less thermodynamic stability. The R2D2/Dcr-2 bounded and reoriented siRNA 
duplex is subsequently loaded into RISC through the interaction between Dcr-2 and 
AGO2 [46]. The strand whose 3’-end is recognized by R2D2 serves as the guide 
strand for mRNA cleavage, whereas the strand whose 3’-end is recognized by Dcr-2, 
termed as passenger strand, will be subsequently cleaved by AGO2 [46, 91]. On the 




loquacious) is one of the key effectors in miRISC, which interacts with both Dcr-1 
and AGO1. R3D1 functions in concert with Dcr-1 in miRNA biogenesis and is 
required for reproductive development in Drosophila [92, 151]. However, it is Dcr-1 
not loquacious that is critical for miRISC assembly [35]. In human, TRBP2 and 
PACT were reported to be involved in the interaction with AGO2 and Dicer [140]. 
The depletion of PACT strongly affects the accumulation of mature miRNA in vivo 
and moderately reduces the efficiency of siRNA induced RNA interference [93]. 
TRBP2 was reported to recruit the Dicer complex to AGO2 for microRNA processing 
and gene silencing [72, 94]. There is no report demonstrating that TRBP2 has the 
ability to sense the thermodynamic stabilities of the bound siRNA duplex and 
determine the fate of the strand. Some of the AGO2 partners discovered by proteomic 
approaches may play the role to sense the thermodynamic stability of the bound 
siRNA [74]. 
2.3.5. Structural understanding of Argonautes 
Typical Argonaute proteins consist of four distinct domains from N-termini to C-
termini: N-terminal, PAZ, Mid and PIWI domains [68] (Figure. 1-4A).  
2.3.5.1. PAZ domain 
PAZ domain is the unique structural motif, which only exists within Dicers and 
Argonautes. The crystal structures of several Argonautes PAZ domains indicated that 
PAZ domain adopts an atypical OB fold (oligonucleotide binding fold, a common 
protein domain for nucleic acids binding) with a deep cleft formed between the β-
barrel and the distinctive appendage comprising a long β-hairpin and a short 　-helix 




demonstrated that 3’-2 nt overhangs of siRNA duplex produced by RNase III 
enzymes is encapsulated within the deep cleft lined with conserved aromatic residues 
[56] (Figure. 1-4B). Biochemical analysis further verified that PAZ domain has the 
preference to recognize 3’-2nt overhangs, which is consistent with the structural 
findings [56]. 
2.3.5.2. Mid/PIWI domain 
PIWI domain adopts an RNase H fold, which indicates that Argonautes are the 
key catalytic component within RISC and are responsible for RISC-mediated 
cleavage activity [55]. Crystal structure of A. fulgidus MID/PIWI protein bound to a 
small dsRNA indicated that 5’-phosphate of the guide strand RNA is anchored by a 
divalent cation at the interface between the PIWI and Mid domains [95, 96, 97] 
(Figure. 1-4C). The crystallographic work also indicated that a conserved DDD/H 
motif (DDD in A.aeolicus, DDH in P. furiosus and human Ago2), which coordinates 
the divalent cation, is absolutely required for the cleavage [67, 68, 97] (Figure. 1-4D 
and 1-4E). Interestingly, the invariable Arg residue within all the Argonaute family 
proteins separates the DDD/H motif from another conserved Glu residue, which 
suggests that this Glu residue may not be involved in substrate cleavage [97, 98]. The 
unique DDD/H-R-E arrangement in space distinguishes Argonaute PIWI domain 
from the traditional RNase H fold protein, which has DDE motif for substrate 
cleavage [99].    
2.3.5.3. Structural insights into Argonaute-mediated mRNA cleavage  
Catalytic cycle model of guide strand-mediated mRNA binding, cleavage, and 




could be anchored within Argonaute by insertion of its 5' phosphate and adjacent base 
into the basic pocket of the Mid domain and insertion of its 3’-2 nt end into the 
aromatic-lined pocket of the PAZ domain [97] (Figure. 1-4E). Derived from this 
model, between the guide strand and the target mRNA starts from 5’ end of the guide 
strand and spans approximately from residue 2-8 nt, and the divalent cation 
coordinated DDD/H motif of the PIWI domain cleaves the phosphodiester bond on 
the mRNA strand precisely between residues 10 and 11, as measured from the 5’ end 
of the guide strand [96]. The relative movement between PAZ- and PIWI-containing 
lobes, which is observed from the comparison of the A. aeolicus AGO structures in 
different conformations, could facilitate the accommodation of guide strands at 
relatively different lengths as well as the insertion, alignment and pairing of the target 
RNAs [96, 100, 101]. The recent crystal structures of T. thermophilus AGO 
complexes demonstrated the critical structural importance of the invariable Arg within 
AGOs, which inserts between the nucleotides 10–11 in the AGO/guide strand binary 
complex and releases the insertion in AGO/guide strand/target RNA ternary complex 
as a consequence of the conformational transition from binary complex to ternary 
complex [98, 102] (Figure. 1-4D).     
3. Diversity of viral suppressors of RNA silencing  
In response to host defense against virus infection by means of RNA silencing, 
viruses encode a wide range of suppressors with various sequences, motifs and 
structures to counter host defense by targeting different steps of RNA silencing 
pathway via different strategies [9] (Figure. 1-1B). For example, Potyvirus helper 
component proteinase (HcPro) suppresses RNA silencing by increasing the stability 




























Figure 1-4. Domain arrangement of Argonautes and their structures.  
A. Schematic representation of Argonaute domains. 
 B. Cartoon representation of human AGO1-PAZ protein bound to small dsRNA with 3′-2 nt 
overhangs. The key residues (F292, Y309, Y314 and L337) lining around the 3′-2 nt 
overhangs binding pocket are highlighted in red. 
C. Cartoon representation of A. fulgidus PIWI/MID protein bound to 5′-phosphorylated 
dsRNA. The key residues (Y123, K127, Q137, K163 and L427) within the 5′-end recognition 
pocket are highlighted in red. 
D. Cartoon representation of Thermus thermophilus Argonaute bound to 5′-phosphorylated 21 
nt DNA and a 20 nt RNA target. The catalytic DDD motif (D478, D546 and D660) and the 
conserved critical R548 are highlighted in red. 
E. Cartoon model for AGO-mediated mRNA cleavage. Both 5′-end and 3′-end of the guide 
strand are anchored by AGO. The mRNA is paired with the guide strand starting from 5′-end 
of the guide strand and spans approximately from residue 2 to residue 8, and the divalent 
cation-coordinated DDD/H motif of the PIWI domain cleaves the phosphodiester bond on the 
mRNA strand precisely between residues 10 and 11, as measured from the 5′-end of the guide 
strand. 
F. Cartoon model of AGO/AGO hook complex. A group of AGO interaction proteins 
comprising a short conserved motif and harboring multiple invariable Trp residues play 
important roles for dsRNA loading into RISC. The AGO hook is located adjacent to the 5′-
end of guide strand recognition pocket. The two invariable Trp residues responsible for 




ringspot virus (CIRV) p19 form a head-to-tail homodimer to sequester siRNA duplex 
[104, 111]. Cucumber Mosaic Virus (CMV) 2b [71] and Polerovirus P0 suppress 
RNA silencing by targeting Arabidopsis AGO1 [105, 106, 107, 108]. Surprisingly, 
Citrus tristeza virus (CTV) encodes three distinct RNA silencing suppressors, p20, 
p23, and the coat protein [109]. Besides the coat protein which is poorly understood, 
the other two suppressors are proposed to bind to dsRNA to interfere with different 
aspects of RNA silencing. p23 is involved in intracellular but not intercellular 
silencing, whereas p20 functions at both levels [109, 110]. However, the structural 
evidence explaining the functional differences of these suppressors is largely 
unknown. In general, although the identified suppressors are dramatically diverse 
within and across kingdoms, they can be mainly divided into two major groups: one 
group of suppressors is targeting dsRNAs whereas the other group is targeting protein 
components involved in RNA silencing pathway. However, even in the same group, 
the exact suppression mechanism could be completely different. For example, P19 
recognizes dsRNA in a length-dependent manner [104, 111], whereas flockhouse 
virus (FHV) B2 protein recognizes dsRNA in a length-independent manner [112, 
113]. In addition, although both CMV2b and P0 target Arabidopsis AGO1 to suppress 
RNA silencing, CMV2b blocks RNA loading into AGO1 [71], whereas P0 recruits 
SCF supercomplex (Skp/Cul1/F-box complex, which is an E3 ligase that mediates the 
ubiquitin transfer from the E2 conjugating enzyme to the targeted substrate) to 
destabilize AGO1 and correspondingly counters RNA silencing [105, 106, 107, 108]. 
Detailed structural analysis of viral suppressors has provided insightful 




suppression. Here, three known suppressor/RNA complex structures are listed to 
provide a current structural understanding in this field. 
3.1. An RNA silencing suppressor encoded by plant virus 
3.1.1. The structure of P19, an RNA silencing suppressor encoded by a 
plant virus 
Both TBSV and CIRV encode p19, a 19 kDa RNA silencing suppressor [104, 
111, 114]. The crystal structures of CIRV and TBSV p19 proteins bound to 19-bp 
siRNA duplex demonstrated that p19 block host RNA silencing by sequestering 
siRNA duplex [104, 111] (Figure. 1-5A). P19 forms a head to tail homodimer 
arrangement, which allows sequestering siRNA duplex via interacting with the 
phosphates and sugar 2’ hydroxyls of the siRNA duplex at its β sheet concave surface.  
Especially there are two sets of tryptophan residues projected form its ‘read head’ α 
helix to stack over the 5’-end bases of siRNA duplex, leading to effective 
measurement of the duplex length. As a consequence, p19 suppresses RNA silencing 
pathway by sequestering siRNA to prevent siRNA from loading into the RISC [103, 
104, 111].  
3.2. RNA silencing suppressors encoded by animal viruses 
3.2.1. The structure of B2, an RNA silencing suppressor encoded by an 
animal virus 
FHV belongs to the Nodaviridae family of nonenveloped icosahedral viruses, a 
positive-sense RNA virus both in vitro and in vivo [112, 113, 115]. FHV B2 is an 
RNA silencing suppressor by binding to both long dsRNA and siRNA duplex [116] 








Figure 1-5. Molecular mechanisms of viral suppressors targeting RNA for RNA silencing 
suppression 
A. TBSV P19 sequesters siRNA duplex in a size-depending manner. P19 adopts a β sheet 
concave platform to bind to siRNA duplex and use a pair of conserved Trp residues projected 
from its ‘read head’ α helix to measure the length of the bound dsRNA. The critical Trp 
residues (W39 and W42) responsible for siRNA duplex length measurement are highlighted 
in red. 
B. FHVB2 binds to dsRNA in a size-independent manner. FHVB2 adopts four-helix bundle 
architecture to recognize two adjacent minor grooves and the intervening major groove of the 
dsRNA without sequence and length-preference. 
C. Human influenza NS1A RBD forms a conserved concave surface to recognize the major 
groove of dsRNA in a length-independent manner. A pair of critical Arg residues (R38) 





forms a dimer to recognize two adjacent minor grooves and the intervening major 
groove of the dsRNA [112].  Unlike P19 homodimer, B2 homodimer provides a four-
helix bundle rather than a 　-sheet platform to recognize the bound dsRNA. The 
majority of the B2-RNA interactions between protein residues and the phosphate 
backbone of RNA are clustered around the two minor grooves, which are recognized 
identically by the symmetric B2 dimer [112]. There are no Tryptophan residues 
projecting from B2 structure to recognize the terminal base of the bound dsRNA, 
therefore B2 could recognize dsRNA in length-independent binding mode.   
3.2.2.  The structure of NS1A, an RNA silencing suppressor ebcided by 
an animal virus 
Non-structural protein 1 from the influenza A virus (NS1A) is a multifunctional 
dimeric protein that participates in both protein-RNA [117, 118] and protein-protein 
interactions [119, 120]. NS1A plays a key role in viral virulence and in countering 
host cell antiviral defenses. NS1A contains an N-terminal RBD and a C-terminal 
effector domain [121, 122, 123, 124]. NS1A RBD domain plays the primary role for 
dsRNA binding but the effector domain also contributes to dsRNA binding. The 
dsRNA binding abilities of NS1A proteins have important roles to protect the viruses 
from human antiviral response during infection. NS1 was reported to shield the 
viruses from the host attacking through the regulation of both cytokine production and 
cytokine sensitivity during influenza A virus infection in primary tracheal epithelial 
cells [125]. 
Recently, our group reported the crystal structure of NS1A RBD bound to a 
self-complementary 21-nt siRNA duplex (19 bp) (Figure. 1-5C) [126]. The structure 




recognize the major groove of A-form dsRNA in a length-independent mode [126]. 
Interestingly, a pair of critical Arg residues from each monomer residing in the middle 
of the concave dsRNA binding surface plays the most important role of dsRNA 
recognition. The side chain of this invariable Arg residue is penetrated into the 
dsRNA helix and forms hydrogen bonds from the phosphate groups of both strands 
simultaneously [126]. Such hydrogen-bond network enables NS1A to anchor the 
bound dsRNA and prevent it from sliding along the binding surface. Since NS1A 
RBD has no corresponding tryptophan residues like those in P19, NS1A binds to 
dsRNA in a length independent manner. Similar to P19 and B2, NS1A RBD is able to 
distinguish dsRNA from dsDNA by forming hydrogen binds with the 2′-hydroxyl 
groups of the bound RNA strand [126]. 
4. Future Prospective 
RNA silencing and its suppression involves a complicated protein-protein and 
protein-RNA interaction between host and pathogen [11]. Structural and functional 
analysis of the key components within this network has already provided helpful 
views to understand the biological processes underlying host-pathogen antagonism 
through millenia of co-evolution [52, 53, 68, 95, 96, 97]. 
However, the current structural focus on the key protein components from 
primitive organisms, such as human parasite Dicer [52, 127] and archea AGOs [56, 
68, 95, 96, 97, 98, 100, 102] reveals limited structural information. The structural 
determination of the full-length eukaryotic Dicer, Drosha, AGOs, Piwi proteins, and 
their interacting partners should be the future mission in this field. Moreover, the 




and human, such as the miRNA processing machinery, holo-RISC and the 
suppressor/host target complexes may be the next challenge in future.  
The recent proteomic approaches to identify novel protein components associated 
with human AGOs have provided a wonderful opportunity for this field to move 
forward [74, 90]. The protein-protein and protein-RNA complexes derived from the 
affinity pull down experiments could be the starting materials for structural analysis 
by cryo-EM approach, which could eventually lead to the structural determination of 
the holo-RISC when supplemented with the X-ray crystal or NMR structures of the 
individual protein components. The proteomic and structural analyses of AGO-like 
system in archea probably will provide interesting structural comparison for 






Part II: Overview of X-Ray Crystallography 
Summary 
Prior to the discovery of X-rays, crystallographers had deduced that crystals are 
made of an orderly arrangement. The discovery of X-rays gives crystallographers a 
powerful tool that could "see inside" of crystals and allow for detailed determination 
of crystal structures. In this chapter, we will briefly go through the X-ray 
crystallography, not in terms of the mathematics, but the general application of this 
method, as well as its past and the possible future in protein structure field.  
1. Introduction  
X-ray crystallography is a method of determining the arrangement of atoms within 
a crystal, in which a beam of X-rays strikes a crystal and scatters into different 
directions [128]. From the angles and intensities of these scattered beams, a three-
dimensional picture of the electron density map within the crystal can be produced. 
On the basis of this map, the positions of the atoms in the crystal can be determined, 
as well as their chemical bonds, their disorder and various other information. The 
method also allows direct visualization of many biological molecules structures, such 
as vitamins, drugs, nucleic acids, as well as proteins, at the atomic or near atomic 
level. X-ray crystallography has also been applied into structural and functional study 
of biology, and also sheds light on chemical interactions and processes, or serves as 





  After Roentgen firstly discovered X-rays in 1895, von Laue, Friedrich, and 
Knipping passed x-rays through crystal of ZnS in 1912, and concluded that crystals 
are composed of periodic arrays of atoms; also crystals cause distinct x-ray diffraction 
patterns due to atoms. Two years later (1914) Bragg and Lawrence showed that 
diffraction pattern can be used to determine relative positions of atoms within a single 
crystal (i.e. molecular structure).  Later Rosalind Franklin collected X-ray diffraction 
data on Na salt of DNA, which guided Watson and Crick to determine that DNA is a 
double helix. In the 1960s, the first hemoglobin and myoglobin structures were solved 
by X-ray diffraction analysis by Perutz and Kendrew, respectively [129, 130]. In 
1980s, the understanding of detergents which play roles in producing crystals from 
membrane-bound proteins led eventually to the structure determination at close to 
atomic resolution of the first membrane protein, the photosynthetic reaction center 
from the purple bacterium Rhodopseudomonas viridis, by Deisenhofer, Huber, and 
Michel [131]. In 1998, MacKinnon determined the first high-resolution structure of an 
ion channel, called KcsA, from the bacterium Streptomyces lividans. It is the first 
time to reveal how an ion channel functions at atomic level [132]. One more 
breakthrough in structural biology field is the determination of the first ribosome 
structures at atomic resolution (ribosome is a huge RNA and protein machine that 
translates RNA sequences into amino acid sequences). First, the 50S subunit from the 
archea, Haloarcula marismortui at 2.4 Å was reported [133]. Soon after, the structure 
of the 30S subunit from Thermus thermophilus at 3.3 Å was published [134]. Shortly 
thereafter, a more detailed structure was published [135]. Early the next year these 
coordinates were used to reconstruct the entire T. thermophilus 70S particle at 5.5 Å 




synthesis, one of life’s most fundamental processes. Another breakthrough in the field 
was the determination of an atomic resolution X-ray crystal structure for the F1 part 
of ATP synthase. It was the first time to connect biochemical data to the three 
dimensional structure of the protein [137].  
Recently, structural biology including X-ray crystallography, NMR spectroscopy, 
as well as computational approaches has been applied into definition of gene function 
through the identification of the likely function of the protein products of genes and 
developed a new subfield known as structural genomics [138]. The 3-dimensional 
information allows protein sequences to be classified into broad groups on the basis of 
the overall shape of the proteins. Structural information can be used to predict the 
preferred substrate of a protein, and thereby greatly enhance the accurate annotation 
of the corresponding gene. Furthermore, it will enable the effects of amino acid 
substitutions in enzymes to be better understood with respect to enzyme function and 
could thereby provide insights into natural variation in genes [138]. Compared with 
the traditional structural biology which pursues structures of individual proteins or 
protein groups, structural genomics aims at structures of proteins on a genome wide 
scale. One main advantage of this approach is economy of scale which results in 
lowering the average costs of structure determination [138].  
In the following sections, I will give a very brief over view about the protein 
crystallography. 
3. Crystals 
X-ray crystallography is totally dependent on highly ordered crystals. The 




purified proteins. Crystals can be grown by slow, controlled precipitation from 
aqueous solution under the conditions that do not denature the protein. The standard 
protocol of protein crystallization is to optimize several solution variables known to 
induce nucleation, such as pH, ionic strength, temperature, and specific concentrations 
of organic additives, salts, and detergent. Among several methods for the 
crystallization of macromolecules, the hanging drop vapor diffusion technique is the 
most popular. The principle of vapor diffusion is straightforward. A drop composed of 
a mixture of protein and well solution is placed in vapor equilibration with a liquid 
reservoir of reagent. Typically the drop contains a lower reagent concentration than 
the reservoir. To achieve equilibrium, water vapor leaves the drop and eventually ends 
up in the reservoir. As water leaves the drop, the sample undergoes an increase in 
relative supersaturation. Both the sample and reagent increase in concentration as 
water leaves the drop for the reservoir. Equilibration is reached when the reagent 
concentration in the drop is approximately the same as that in the reservoir. 
4. X-ray Diffraction  
The goal of data collection is to determine the indices and record the intensities of 
as many reflections as possible, as rapidly and efficiently as possible. The section 
includes X-ray sources, which produce an intense, narrow beam of radiation, and 
detectors.  
X-ray is an electromagnetic radiation with wavelengths in the range from 0.1 to 
100 Å. X-rays in the useful range for crystallography can be produced by bombarding 
a metal target (most commonly copper or molybdenum) with electrons produced by a 
heated filament and accelerated by an electric field. When a high voltage difference is 




thermionic emission, hit the anode and X-rays are produced.  Depending on the target 
and transition, the radiation is named as Cu K　, Cu K　 etc. 
There are three common X-ray sources, X-ray tubes (actually a cathode ray tube), 
rotating anode tubes, and particle storage rings (which produce synchrotron radiation 
in the X-ray region). In a rotating anode type X-ray generator, the anode is rotated by 
a motor and a high intensity beam is produced.  In a synchrotron, electrons travel in a 
storage ring at a high speed and are emitted as radiation. There are several advantages 
of synchrotron sources. First is efficiency. X-ray data that requires several hours of 
exposure to a rotating anode source can often be obtained in minutes or even shorter 
at a synchrotron source. Second is the changeable wavelength. It is possible to change 
the wavelength of synchrotron radiation and the selectable wavelength can be helpful 
in solving the phase problem.  
Crystals are regular arrays of atoms, and the atoms scatter X-ray waves primarily 
through the atoms' electrons. A regular array of scatterers (the electrons) produces a 
regular array of spherical waves. Although these waves cancel one another out in 
most directions through destructive interference, they add constructively in a few 
specific directions, determined by Bragg's law:  
2dsinθ = n λ 
Here d is the distance between diffracting planes, θ is the incident angle, n is any 
integer, and λ is the beam wavelength. These specific directions appear as spots on the 
diffraction pattern called reflections. Thus, X-ray diffraction results from an 
electromagnetic wave (the X-ray) impinging on a regular array of scatterers (the 




The reflection intensities can be measured by scintillation counters, which in 
essence count the X-ray photons and thus give quite accurate intensities over wide 
range. Scintillation counters contain a material that produces a flash of light when it 
absorbs an X-ray photon. A photocell counts the flashes. The simplest X-ray detector 
is X-ray-sensitive film, but the film has been almost replaced by image plate and 
charge-couple devices (CCD) recently. Image plate detectors can store diffraction 
images reversibly and have capacity to record reflections of widely varying 
intensities. However, one disadvantage of the image plate is that the reading of data 
and the feeding into computer have to be done separately. Another is area detectors, 
which not only combine the accuracy and wide varying range of scintillation 
counting; the simultaneous measurement of many reflections, but also has the 
advantage of direct collection data by computer. CCDs detectors are one of the area 
detectors, which are photon counters, solid-state devices that accumulate charge in 
direct proportion to the amount of light that strikes them.  
5. Data collection 
X-ray Data collection is a central part of protein crystallography. Briefly, a crystal 
is placed between an X-ray source and an X-ray detector. The crystal lies in the path 
of a narrow beam of X-rays coming from the source. A simple detector is X ray film, 
which when developed exhibits dark spots where X ray beams have impinged. These 
spots are called reflections because they emerge from the crystal as if reflected from 




6. Structure Determination  
A prerequisite of the protein crystals’ structure solution is to find an isomorphous 
heavy atom derivative of the native protein. Isomorphous means that the derivative 
protein crystal structure should be identical to the native one except for the presence 
of the heavy atoms bound to protein molecules. The packing of the protein molecule 
should not be affected by the heavy atoms. The most common method of heavy atom 
inclusion is to soak the native protein crystals in a solution containing a heavy atom 
compound, or co-crystallized with heavy atoms. Other more recent methods involve 
the production of protein with modified amino acid residues. One of the common 
methods is the replacement of   sulphur of the methionine containing in the protein 
with selenium.  
In a diffraction experiment one can only measure the intensities and diffraction 
angles of the diffracted beams. But the phases of the diffracted X-rays can not be 
measured. This phase information along with the amplitudes of the diffracted X-rays 
is essential for the crystal structural determination.   
Currently, there are three approaches to solve the phase problem including direct 
method, molecular replacement, and isomorphous replacement method. 
6.1. Direct method 
Direct method is generally applied into small molecules and has only recently 
been applied to the solution of small proteins containing about 100 amino acid 
residues. This approach is in general not applicable to proteins since the heavy atom 




This approach can make estimates about the reflection phases using assumptions 
about the internal structure of the crystal. And it requires X-ray diffraction data that 
extends to atomic resolution, around 1.0Å resolution. Direct method is for estimating 
the phases of the Fourier transform of the scattering density from the corresponding 
magnitudes. The methods generally exploit constraints or statistical correlations 
between the phases of different Fourier components that result from the fact that the 
scattering density must be a positive real number.  
6.2. Molecular Replacement (MR) 
MR relies on the existence of a known related structure. The idea is to find the 
rotation and translation which position the model structure in the unit cell so as to 
give the highest correlation between experimental diffraction measurements and those 
calculated from the model. This method is likely to become more and more applicable 
as the number of solved protein structures increases in the future. 
6.3. Isomorphous replacement method  
The third and most prominent of the solutions to the phase problem in protein 
crystallography is isomorphous replacement methods. In these methods phase 
information is retrieved by making isomorphous structural modifications to the native 
protein, usually by including a heavy atom and then measuring the diffraction 
amplitudes for the native protein and each of the modified cases. If the position of the 
additional heavy atom or the change in its scattering strength is known then the phase 
of each diffracted X-ray can be determined by solving a set of simultaneous phase 




(SIR), Multiple Isomorphous Replacement (MIR), Single Isomorphous Replacement 
(SIR), and the Multiple wavelength Anomalous Diffraction method (MAD).  
MIR is possibly the most prominent solution to the phase problem in 
macromolecular crystallography.  MIR method requires soaking the protein crystal 
with heavy atoms solution or co-crystallization with the heavy atoms. Data sets from 
the native and heavy-atom derivative of the sample are firstly collected. The addition 
of the heavy atoms has little effect on unit cell dimensions in comparison to its native 
form; hence, they should be isomorphic. The heavy atom's location in the unit cell is 
then retrieved on the basis of interpretation of the Patterson difference map. The phase 
of each diffracted X-ray can be determined by solving a set of simultaneous phase 
equations.  
MAD is another technique applied in structure determination of such biological 
macromolecules as proteins by the solution of phase problem. It is possible if the 
structure contains one or more atoms that cause significant anomalous scattering from 
incoming X-rays at the wavelength used for the diffraction experiment. Atoms in 
proteins which are suitable for this purpose are sulfur or heavier atoms such as metal 
ions in metalloproteins. The most commonly used atom for phase determination via 
MAD is selenium, since it is usually possible to replace the natural sulfur containing 
amino acid methionine by selenomethionine. The application of the MAD technique 
is much more convenient than the MIR method, which requires the preparation of 
heavy atom derivatives in a trial-and-error approach. 
Compared to MAD, the method of Single-wavelength anomalous diffraction 




technique is the minimization of time spent in the beam by the crystal, thus reducing 
potential radiation damage to the molecule while collecting data. 
7. Conclusions 
Almost half-century has passed by after the first determination of protein crystal 
structure, and more than 45,000 structures from single polypeptides to large complex 
have been reported. The challenge for crystallographers, however, still remains the 
growing of a diffracting crystal.  Fortunately, methodology of X-ray crystallography 
makes great progress. For example, automation of these crystallization processes for 
high-quality protein crystals by robots enables this tedious job become increasingly 
easily and efficiently. Moreover other techniques such as Cryo-EM which does not 
require crystallized samples attract more attention. Cryo-EM is generally applied into 
the determination of the structure of extremely large proteins and protein complexes, 
but structures determined by Cryo-EM are typically of lower resolution (around 20-
30Å) than those derived from X-ray Crystallography or NMR. But currently scientists 
have greatly improved Cryo-EM and reported a 4.5 Å resolution structure of a 22-
MDa macromolecular assembly, the capsid of the infectious epsilon15 (epsilon15) 
particle, by single-particle electron cryomicroscopy [139].  
Right now, structural biologists are developing high-throughput methods for 
solving more complex structures, and reaching out to the broader scientific 
community to explore the function and potential biomedical impact among different 
protein structures. Such developments no doubt will advance our knowledge of 




Objectives of the Projects 
1. Many AGOs’ partners that involved in RISC complex play important roles in 
RNA silencing pathway, however the function and mechanism of the majority are 
not addressed. In the first project of this thesis, we focus on kiaa1093, which is a 
human AGOs’ interaction partner. The purpose of this project is to determine the 
structure of kiaa1093 RRM and to explore the function of kiaa1093 RRM in the 
context of RNA silencing pathway.  
2. 2b proteins encoded by cucumovirus act as PTGS suppressors to counter host 
defense during infection. Second project in this thesis is to explore the suppression 
mechanism of RNA silencing displayed by TAV2b; to explore the binding mode 
of TAV2b with small RNAs; to identify the key residues involved into RNA-
protein interaction by the determination of the TAV2b/21siRNA complex 
structure.  
Significance of the Projects 
1. Although the RRM is one the most extensively studied RNA-binding domains, 
both in terms of structure and biochemistry, the high variety of interaction 
partners makes the mechanistic role and the function of the RRMs not easy to 
decipher. The structure determination of kiaa1093 RRM should give us a unique 
opportunity to postulate the function of kiaa1093 and therefore provide important 
insights to understand the mechanism of RNA silencing.    
2. RNA silencing and its suppression involve a complicated protein-protein and 
RNA protein interactions between the host viruses. Detailed structural analysis of 




understand this host-pathogen relationship and further to understand the diverse 




Chapter Two: Materials and Methods 
1. Bacterial strains and media 
Escherichia. coli DH5α strain is used as host for cloning experiments whereas 
BL21 (DE3) strain is used for protein expression. Both E. coli starins are grown in LB 
media at 37°C with vigorous shaking (250 rpm).  
LB liquid medium (pH 7.5) containing 1% Bacto®- tryptone, 0.5% Bacto®- 
yeast extract, and 0.5% NaCl is  autoclaved at 121°C for 20 min and cooled at room 
temperature. LB agar plate is prepared as follow: LB medium with 1.5% Bacto®- 
agars, containing proper antibiotics.  
2. Plant materials and Argro-infiltration  
2.1. Maintenance of plant material.  
Wild type Nicotiana benthamiana and 16 C line (GFP transgenic line) used for 
in vivo experiments are grown under the conditions of 16h light and 8h dark at 25°C.  
2.2. Argro-infiltration.  
Interested fragments are cloned between the Cauliflower mosaic virus (CMV) 
35S promoter and terminator in the binary plasmid pBA (GenBank accession no. 
AF234296) vectors and generate constructs for infiltration. These plasmids are then 
transformed into Agrobacterium tumefaciens strain EHA105 by electroporation (Gene 
pulser-Xcell BioRAD) and selected in LB medium containing proper antibiotics. The 
leaf infiltration of A. tumefaciens strains is performed in transgenic N. benthamiana 
homozygous for the GFP transgene (line 16c). The GFP fluorescence expression in N. 




high intensity ultraviolet lamp, Spectronics, USA; www.spectroline.com) and 
photographed by a Nikon D-80 digital camera with a yellow filter. 
3. DNA manipulation 
3.1. Amplification of DNA by polymerase chain reaction (PCR) 
DNA fragments and interested genes are amplified by the basic polymerase chain 
reaction (PCR). Taq PCR Master Mix Kit (QIAGEN) is used for this purpose. This kit 
provides QIAGEN Taq DNA Polymerase in a premixed format. This ready to-use 
solution includes Taq DNA Polymerase, PCR Buffer, MgCl2, and ultrapure dNTPs at 
optimized concentrations. The composition of PCR reaction mixture is shown as 
following: 25 µl PCR mix solution, 1 µl forward Primer (100µM), 1 µl reverse Primer 
(100µM), 1 µl DNA templates (20-100 ng/µl), 22µl distilled water top up to 50 μl 
final volume. The PCR is running on Peltier Thermal Cycler (DNA engine BioRad) 
with the following program. 1 cycle of   95°C for 15 minutes, 5circles of each at 94°C 
for 45 seconds, 48°C for 45 seconds, and 72°C for 3 minutes; 30 circles of each at 
94°C for 45 seconds, 58°C for 45 seconds, and 72°C for 1 minute per Kb; 1 circle of 
72°C for 10 minutes; 1 circle of 4°C forever. And the primers used in this thesis are 
listed in table 2-1. 
3.2. Agarose gel electrophoresis and DNA purification 
PCR products are separated by 1% agarose gel with 0.5 µg/ml ethidium bromide 
(EB) electrophoresis in TAE buffer (0.04M Tris-acetate, 0.001 M EDTA, pH 8.0) 
along with a standard DNA ladder (Fermentas) under constant voltage of 120 V for 15 







Kiaa1093 RRM in Pet 28M(BamH1/Xhol1) 
Forward (1-21) cgcggatcc AGTTACTGGCTGGTTCTTCAC 
Reverse (1-255) ccgctcgagCTGAGCTTGTGCCAGAAAGCGGCTGAC 
Reverse (194-219)  ccgctcgagAGTGGCAAACTCAGCAAGGATGGTAG 
TRBP domains in PGEX 6p.1(BamH1/Xhol1) 
Forward (1-21) cgcggatcc ATGAGTGAAGAGGAGCAAGGC 
Forward (450-471) cgcggatcc GTCTCCCCTCAGCAGTCTGAG 
Forward (877-898) cgcggatcc GCCTGCTGCCGTGTCCTCAGTG 
Reverse (280-300) ccgctcgag CATGCTCCCCCCTTTGAGGTG 
Reverse (670-690) ccgctcgag CAGAGGCACCGTGTGCACTCG 
Reverse (1081-1098) ccgctcgag CTTGCTGCCTGCCATGAT 
TRBP domains with C-terminal Fusion Flag tag in PGEX 6p.1(BamH1/Xhol1) 
Reverse (280-300) Flag  ccgctcgag CATGCTCCCCCCTTTGAGGTG 
Reverse (670-690) Flag ccgctcgag CAGAGGCACCGTGTGCACTCG 
Reverse (1081-1098) Flag ccgctcgag CTTGCTGCCTGCCATGAT 
 




UV light (365 nM) and then purified by the QIAGEN Gel Extraction kit according to 
the manufacturer’s instructions.  
3.3. DNA digestion and ligation 
DNA digestion and ligation are conducted based on the manufacturer instruction. 
The DNA digestion mixture is composed of 100 ng DNA, 1 µl restriction enzymes 
(NEB), 1 μl 100×BSA, and top up to 100 μl by water. The digested DNA products are 
further seperated by agarose gel (1%) electrophoresis and purified by QIA quick Gel 
Extraction Kit (QIAGEN). Rapid DNA Ligation Kit (Roche) is applied to ligate the 
digested DNA fragments to the digested vectors. The reaction is composed of 1 μl T4 
ligase, 10 μl 2× ligase buffer, proper amount of inserts and vectors, top up to 20 μl by 
distilled water. The ligation is performed at room temperature for 10-30 minutes.  
3.4. Preparation of E.coli competent cells 
Freshly growing E. coli colonies from LB agar plates are inoculated into 100 ml 
of LB media without antibiotics and then are grown at 37°C with vigorous shaking 
(250 rpm). After the cells grow to an OD600 value of 0.6, the culture is chilled on ice 
for 15 min and then the cells are collected by centrifugation at 4,000 rpm for 10 min 
at 4°C. The cell pellet is re-suspended in 50 ml of ice-cold and sterile 0.1mM CaCl2 
with 15% glycerol, and incubates on ice for another 15 min. After centrifugation, the 
cell pellets are re-suspended by 4ml 0.1mM CaCl2 with 15% glycerol. The competent 
cells can be either used immediately or quickly frozen as 50 ~100 μl aliquots in liquid 




3.5. Transformation of bacterial cells 
Frozen competent cells (50 μl) are thawed on ice. The competent cells are mixed 
gently with either the transforming plasmid or ligation products (10-100ng). After 
incubated on ice for 30 minutes, the mixture of cells and DNA are subjected to be 
heat-shocked at 42°C for 45 seconds and immediately chilled on ice for another 2 
minutes. After addition of 400 μl of fresh LB, the cells are incubated at 37°C for 45 
min to 1 hour with vigorous shaking. Subsequently, the cells are plated onto selection 
plates with appropriate antibiotic and finally incubate at 37°C overnight. 
3.6. Purification of plasmids from bacteria 
For small scale plasmid extraction, 2-3ml overnight cell culture is enough. Single 
colony is picked and cultured in 2 ml of LB containing appropriate antibiotics with 
vigorous shaking at 37°C overnight. Cells are harvested by 5000 rpm for 3 min, 
followed by purification with the Qiagen QIAprep Miniprep Kit according to the 
manufacturer’s instructions.  
For the large scale plasmid extraction, 100ml or more overnight culture is 
required. 
Prepare 100ml to 300ml over night culture and pellet the cells at 6000 rpm for 10 
minutes at 4°C. And then extract plasmids by using Qiagen plasmid Maxipreb 




3.7. Screening of transformants by restriction digestion and DNA 
sequencing 
The plasmids are digested with same restriction enzymes (NEB) as those in 
ligation reaction and then identified by agarose gel electrophoresis. The plasmids 
containing correct size of insert are processed to sequencing. 
3.8. DNA sequencing 
      Sequencing reaction is set up for 20 μl of volume containing 50 μg of DNA 
template, 0.1μl forward or reverse primer (100μM), and 8 μl of BigDye terminator 
reaction mixture (ABI PRISM TM Dye terminator Cycle Sequencing Ready Reaction 
Kit). The cycle sequencing is performed on the Peltier Thermal Cycler (DNA engine 
BioRad) as follows: 25 cycles of each 96°C for 10 seconds, 50°C for 10 seconds, 
60°C for 4 min; rapid thermal ramp to 4°C forever. The reaction product is purified 
by ethanol precipitation then applied to the ABI PRISM 3100 automated sequencer. 
3.9. Site-directed mutagenesis 
DNA mutants are generated by using the QuikChange Site-Directed Mutagenesis 
Kit (Stratagene; www.stratagene.com). Briefly, synthesize two complimentary primers 
containing the desired mutation, flanked by unmodified nucleotide sequence. Series of 
sample reaction is prepared as following:  5 μl of 10× reaction buffer; 50 ng of 
dsDNA template; 125 ng of oligo nucleotide primer 1; 125ng μl of oligo nucleotide 
primer 2; 1 μl of dNTP mix; and top up with ddH2O to a final volume of 50 μl. Then 
add 1 μl of PfuTurbo DNA polymerase. The program of one circle of 95°C for 30 
seconds; 18 circles of  each 95°C for 30 seconds, 55°C for 1 minute, and 68°C for 1 




Thermal Cycler. Next to add 1 μl of the Dpn I restriction enzyme directly to each 
amplification reaction and incubate at 37°C incubated for 1 hour to digest the parental 
(i.e. the non-mutated DNA) supercoiled dsDNA. Finally transformed the 10 μl of the 
Dpn I-treated DNA to DH5α competent cells and then spread on LB plates with 
certain antibiotics.  
4. Protein manipulation 
4.1. Protein expression and solubility test 
The interested DNA fragments are cloned into expression vectors. The constructs 
encoding target proteins are transformed into BL21 competent cells. Briefly, cells are 
cultured in LB media containing appropriated antibiotics at 37°C with vigorous 
shaking to reach an OD600 value from 0.6 to 0.8. And then the cells are induced by 0.4 
mM isopropyl-ß-D-thiogalactopyranoside (IPTG) overnight at 20°C. Next day, cells 
are harvested by 4000 rpm for 15 minutes. The pellet is resuspended in buffer (25mM 
Tris (pH 7.5), 25 mM KH2PO4, 500mM NaCl, 10% glycerol, and 1mM DTT). And 
the cell suspension is broken by Homogenizers (High-Pressure EmulsiFlex-C3, 
Avestin) and centrifuged by 40K rpm for 1 hour at 4°C. The supernatant and pellets 
are separately tested by SDS-PAGE gel to determine the solubility of the fusion 
proteins expressed.  
4.2. Expression of Seleno-Methionine substituted protein 
The selenomethionine (Semet) substituted protein is expressed in 1×M9 medium. 
5×M9 stock solution is prepared as follow: weigh 56.5 g M9 minimal medium salt 
mixture (including Na2HPO4, KH2PO4, NaCl, and NH4Cl) and dissolve to 1 litter by 




following: 5×M9 salt solution 200ml, 1M MgSO4 2ml, 20% glucose 20ml, 0.05M 
CaCl2 2ml, then top up to 1 litter with sterile distilled water. All the items should be 
steriled. The amino acids mixture for 1litter media is prepared as following: L-Lysine 
(100mg), L-phenylalanine (100mg), L-threonine (100mg), L-Isoleucine (50mg), L- 
leucine(50mg), L-Valine(50mg).   
Grow overnight culture in 3ml LB media with proper antibiotics at 37°C. Spin 
down the overnight culture and re-suspend the pellet in 30ml 1× M9 media with 
proper antibiotics and grow the cell at 37°C form the early morning till late night. 
Dump the 30ml culture into 300ml fresh 1×M9 media with antibiotics and grow the 
cell overnight at 37°C. Add 25ml overnight culture to 1 litter fresh M9 media with 
antibiotics and grow the cell until OD600 value reach to 0.6-0.8. Add amino acids 
mixture (450mg) mentioned above plus Sleno-DL-methionine (25mg) to each flask 
and continue to grow at 37°C for 15 minutes. Add IPTG (0.4mM) and adjust the 
temperature to 20°C for overnight induction.   
4.3. Protein Purification 
All the protein purification operations are performed at 4°C by using ÄKTA 
explorer or ÄKTA prime plus purification system (GE). Proteins are purified using 
the following techniques on the basis of proteins’ specific properties. The general 
techniques are listed in the Table 2-2. 
4.3.1. Protein purification by Affinity chromatography  
4.3.1.1. GST fusion protein purification and removal of GST tag 
The supernatant containing target proteins is applied to Glutathione Sepharose 4B 




column volumes (CV) of STE buffer (500mM Nacl, 10mM Tris (pH 8.0), 1mM 
EDTA 2mM DTT, and 10% glycerol). The bound proteins are eluted by 20 mM 
reduced glutathione which is freshly prepared. The fractions containing target proteins 
confirmed by SDS-PAGE gel are pooled together. ProScission protease is applied to 
remove GST tag at 4°C overnight with rotation.  To separate GST from the target 
protein, there are several methods can be used. First, after digestion, the mixture 
containing both GST and target proteins are dialyzed in 100mM NaCl and 25mM Tris 
(pH 7.5), and then, the protein mixture is reloaded into the Glutathione Sepharose 4B 
column. The GST protein will be rebound to the column, while the target protein 
which has no GST tag will be left in the flow through. If this method failed, the ion 
exchange chromatography and gel filtration can be considered, which will be 
discussed later.  
4.3.1.2. Polyhistidine (HIS) fusion proteins or HIS-SUMO fusion protein 
purification and removal of HIS or HIS-SUMO tags 
The cell lysates are loaded to His trap column (GE) at 1 ml/min and then followed 
by elution with 25mM, 250mM, 500mM, and 750mM immidazle successively in 
buffer (250mM NaCl, 10% glycerol, and 10mM Tris (pH 7.5)). The fractions 
containing target proteins confirmed by SDS-PAGE gel are pooled together, and then 
dialyzed in 50mM NaCl and 25mM Tris (pH 7.5). For N-terminal HIS tagged 
proteins, the tag is cleavage by Thrombin, whereas HIS-SUMO tagged proteins is 
cleavage by ULP-1. Similar to the removal of GST tag, the HIS / HIS-SUMO tags can 
be separated by reloaded the mixture onto Histrap column after the removal of 




4.3.1.3. Heparin affinity chromatography 
Heparin affinity chromatography is specially used to purify DNA/RNA binding 
protein. Immobilized heparin is group-specific purification of RNA and DNA binding 
proteins. This methodology takes advantage of heparin's similar properties to RNA 
and DNA, i.e. negatively charged sugar molecule. Moreover, Heparin also functions 









Table 2-2. The general techniques of protein purification used in this thesis. 
Property Technique 
Ligand specificity Affinity chromatography 
Net charge Ion exchange chromatography 




with salt is most commonly used in both cases. The usage of Heparin column (GE) is 
same as SP/QP column (GE) which will be discussed in next paragraph.  
4.3.1.4. Protein purification by ion exchange chromatography 
Ion exchange chromatography separates proteins according to the difference of 
their net charge, i.e. the isoelectric point (PI). SP and QP column can be used for this 
purpose. SP column is suitable for the proteins with PI above 7.0, whereas QP column 
is better for the proteins with PI lower than 7.0. Protein sample is dialyzed in 50mM 
NaCl and 25mM Tris (pH 7.5). After the sample is loaded into the proper column at 
1ml/min, proteins are eluted by gradient monoB buffer at 3ml/min (1M NaCl, 25mM 
Tris (pH 7.5), 0.4mM DTT, and 0.1mM EDTA). Fractions containing target protein 
conformed by SDS-PAGE gel are collected. 
4.3.1.5. Gel filtration  
Gel filtration separates proteins on the basis of proteins’ molecular size. The 
protein solution is loaded onto Hiload 26/60 column (GE) with gel filtration buffer 
(25mM Tris (pH 7.5), 500mM NaCl, 0.5mM EDTA, 4mM DTT) at flow-rate of 
2.5ml/min. After 1.5 column volume (CV) elution, fractions containing target protein 
conformed by SDS-PAGE gel are collected.  
5. Crystallization  
Crystallization screens are performed using the vapor diffusion hanging-drop 
method by mixing 1ul screening buffer with 1ul protein sample with proper 
concentration in Hampton 24-well plastic plates at 4 or 20°C. The initial screens are 




conditions are optimized to get diffraction quality crystals. The crystals are mounted 
and then soaked into the cryo-protectant buffers successively (well solution with 10%, 
15%, and 30% glycerol, respectively) before flash frozen in liquid nitrogen for data 
collection. 
6. Data collection and structure determination 
For data collection, crystals are flash frozen (100K) in the above reservoir solution 
supplemented with 30% glycerol. A total of 360 frames of 1° oscillation are collected 
for each crystal. The data are collected on beamline X12C at the National Synchrotron 
Light Source at Brookhaven National Laboratory and are processed by HKL2000 
(www.hkl-xray.com).  
The crystal structure of kiaa1093 RRM is determined by single wavelength 
anomalous diffraction using SOLVE/RESOLVE (http://www.solve.lanl.gov), and the 
SAD phase is calculated and improved by density modification assuming a solvent 
content of 48% using the SHARP program (http://www.globalphasing.com). On the 
other hand, the structure of TAV2b is determined by multiwavelength anomalous 
dispersion using SHARP (www.globalphasing.com). The models are built by using the 
program O (http://xray.bmc.uu.se/alwyn) and refined using REFMAC/CCP4 
(www.ccp4.ac.uk).  
7. Protein analysis 
7.1. SDS-PAGE gel 
Proteins samples are separated by SDS-PAGE gel on the basis of their molecular 

































5% 0.67 1.25 0.025 0.025 15 3.075 5 




1.5MTris (pH 8.8) (ml) 7.5 7.5 
10% SDS(µl) 150 150 
10% APS(µl) 150 150 
TEMED(µl) 20 20 
Water(ml) 10.2 7.2 




provided by the manufacturer (Mini-PROTEAN Tetra Cell, BioRad). 12% and 15% 
SDS-PAGE gel for the routine analysis are prepared as shown in table 2-3. Protein 
samples are boiled for 5 minutes with 2× loading buffer (100mM Tris (pH6.8), 
200mM DTT, 4% SDS, 0.2% bromophenol blue, 20% glycerol). The gel is running in 
buffer (Tris Base 3g, glycine 14.4g, SDS 1g, and top up to 1 litter with ddH2O) under 
constant 160 V, and then change to 180V when the dye is running into the separation 
gel. After electrophoresis, the gel is stained by Coomassie staining solution (45% 
methanol, 10% acetic acid, and 0.25% coomassie brilliant blue R-250) for half of an 
hour and then destained by 5% methanol and 7.5% acetic acid. The destained gels are 
dried after washing by water to remove the organic solvents. 
7.2. Flag affinity Pull down assay  
Bait proteins with a fusion Flag tag and prey proteins with His tag are over 
expressed and purified, separately. 20 µl of anti-FLAG M2 agarose beads (Sigma) are 
re-suspended in 500 µl binding buffer (0.1 M KCl, 5 mM MgCl2, 10% glycerol, 0.1% 
Tween20, 10 mM β-mercaptoethanol, 0.2 mM  PMSF, and 20 mM Tris-HCl (pH 8.0)) 
and incubated with 2.5 µmol bait proteins for 3 hours at 4ºC with rotation. The beads 
are followed by washing with washing buffer for 3 times (500mM NaCl, 5mM 
MgCl2, 0.1% NP40, and 50mM Tris (pH 7.5)). Next the affinity bound complexes are 
resuspended by 500 µl binding buffer and then incubated with prey proteins (10 
µmol) for another 4 hours followed by three times washing by washing buffer.  
Finally, the beads are pelleted and resuspended in protein sample loading buffer, 
incubated for 5 min at 95ºC, and pelleted again. Bound proteins are analyzed by 




7.3. Western blotting  
Western blotting experiment includes the following steps. First, protein samples 
are resolved by SDS-PAGE gel electrophoresis. Second step is electrophoretic 
transfer to PVDF Membranes in buffer (Tris base 3g, Glycine 14.4 g, Methanol 200 
ml, top up to 1 litter with ddH2O) at constant voltage of 100V for 1-2 hours at 4°C.   
Next step is blocking. After the electrophoretic transfer is completed, the membrane is 
blocked with 5% non-fat milk in TBST buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 
0.05% (V/V) Tween-20) for 1 hour at room temperature on an orbital shaker. Forth 
step is incubating membrane with primary antibody which is diluted proper times with 
TBST buffer for 1 hour at room temperature with shaking. To remove the unbound 
primary antibody, the membrane must be washed by TBST buffer at least 10 minutes 
three times. Next, the membrane is incubated with the TBST-diluted second antibody 
(usually in a 1:5000 dilution). The unbound second antibodies are washed away as 
aforementioned. The fluorescence produced by the HRP (horseradish peroxidase) -
conjugated second antibody is detected with the Amersham ECL™ Western Blotting 
Detection Reagents following the manufacturer protocol. 
7.4. Electrophoretic Mobility-shift assay (EMSA) 
EMSA experiment is performed by using LightShift® Chemiluminescent EMSA 
Kit (Pierce) includes the following steps, labeling RNA and/or DNA with biotin; 
binding reaction, electrophoresis and electrophoretic transfer to nylon membrane, and 
then detect biotin-labeled DNA by chemiluminescence.  
In this thesis all the RNA sequences except the 21 ssRNA are designed as self-
complementary mode. The sequences of small RNAs or DNAs are listed in table 2-4. 




following the manufacturer’s protocol. The nucleic acids labeled by biotin are stored 
at -20°C. Interested proteins and biotin labeled RNA/DNA are incubated at room 
temperature in the binding reaction system (20 μl) which contains binding buffer 2 μl 
(10mM Tris (pH 7.5), 50mM KCl, 1mM DTT), 1mM MgCl2, proper amount of 
protein and the biotin labeled small RNA/DNA, and ddH2O top up to 20 μl). Binding 
reactions incubate at room temperature for 20-30 minutes. Before electrophoresis, the 
4-6% native gel is needed to pre-run in 0.5× TBE buffer (45 mM Tris, 45 mM Boric 
Acid, 1mM EDTA, pH 8.3). After the incubation, samples are loaded to native gel 
after the addition of 5× native loading dye. And then run the native gel at a constant 
voltage of 100V in 0.5× TBE buffer until the bromophenol blue dye has migrated 
approximately 2/3 to 3/4 down the length of the gel. Next is electrophoretic 
transferring the binding reactions to nylon membrane in 0.5× TBE at constant voltage 
of 100V at 4°C for 1 hour following the manufacturer’s instructions. When the 
transfer complete, cross-link the biotin labeled RNA/DNA to membrane at 
120mJ/cm2 as soon as possible by a UV-light cross-linker instrument equipped with 
254 nm bulbs. 
Finally is detection of EMSA followed manufacturers’ instruction. Membrane is 
blocked by the block buffer at room temperature for half hour. And then incubated 
that with Stabilized Streptavidin-Horseradish Peroxidase Conjugate in blocking buffer 
(1:300 dilution). Next to washing step by 1×washing solution four times for 5 
minutes. After complete washing, membrane is incubated with substrate equilibration 
buffer.  And then place the membrane in a film cassette and expose to X-ray film for 
2-5 minutes. Develop the film according to manufacturer’s instructions.  




Freeform proteins or complex are analyzed on Superdex 200 10/300 GL column (GE) 
at flow rate of 0.5 ml/min and an injection volume of 0.1ml. All the experiments are 
performed in 25 mM Tris base and 100mM NaCl (pH 7.5). For the complex, protein 
and RNA (at the ration of 9 to 10) are incubated on ice for 10 minutes. The column is 
firstly calibrated by the low molecular weight gel filtration kit (GE), and the 
corresponding curves are established by OriginPro 7.5.  
7.6. Isothermal Titration Calorimetry (ITC)  
ITC experiments are performed using a Microcal VP-ITC calorimeter. All the 
experiments are performed in a buffer containing 25mM Tris (pH 7.5) and 100mM 
NaCl. After filtered and degassed, substrate (20 mM) and ligand (200 mM) are loaded 
into the cell and syringe respectively with a stirring speed of 310 rpm (Microcal VP-
ITC calorimeter, Northampton, MA). Data are collected in the high feedback mode 
with a filter period of 3s. The calorimetric data are processed and fitted into the single 
set of identical sites model using Microcal Origin (version 5.0) and analyzed by the 










Small RNAs Sequence  
21nt ssRNA 5’-P-UGGGGGGGGGGGGGGGGGGGG-3’ 
9nt siRNA 5’-AGUUACUUU(m)-3’ 
12nt dsRNA 5’-P-GCGCGCGCGCGC-3’ 
21nt siRNA 5’-P-AGACAGCAUUAUGCUGUCUUU-3’ 
32nt siRNA 5’-AGACAGCAUAUGCAUGCGCAUAUGCUGUCUUU-3’ 
26nt dsDNA 5’-CCTTAGTTGACCTAGGTCAACTAAGG-3’ 
 
Table 2-4.  Small RNAs and DNAs sequences used in this thesis  
  
 
Chapter Three: Characterization of Kiaa1093 




 RISC is a multi-protein complex that incorporates Argonautes and the bound 
small RNA, the minimum functional unit of RISC. The function While recent 
research pay more attention on the AGOs partners in this supercomplex, the function 
and molecular mechanism of RISC become increasingly clear. Among these RISC 
components, Dicer and TRBP are extensively studied, whereas kiaa1093 is poorly 
understood. In this study, we solve the crystal structure of kiaa1093 C-terminal RNA 
recognition motif (RRM) which shows that kiaa1093 RRM harbors an extra C-
terminal α helix besides the typical RRM fold. We also demonstrate that this RRM is 
a protein binding domain and bridge the kiaa1093’s interaction with TRBP. Also, the 
additional C-terminal α helix plays very important role in TRBP and kiaa1093’s 
interaction. More interestingly, the kiaa1093 RRM enhance TRBP’s RNA binding 
affinity. 
1. Introduction 
The current research on Argonautes’ partners has greatly enriched the contents 
of the RISC complex. The biochemical analysis of human AGO1- and AGO2-
  
 
containing protein complexes indicated that most of human AGO1 and AGO2’s 
partner proteins are RNA binding proteins [74, 90].  
Among these interacting partners, Dicer is possible the most critical, which 
directly binds to PIWI box of human AGO2 [75, 76]. The direct interaction between 
Dicer and AGO indicates that Dicer plays important roles in both small RNA 
maturation and RNA loading into Argonautes. Besides Dicer, other proteins involved 
into the RISC also play important roles in RISC function.  
One is human immunodeficiency virus (HIV)-1 transactivating response 
(TAR) RNA-binding protein (TRBP), a human homolog of loqs [74, 90]. TRBP is 
required for both siRNA or miRNA mediated RNA silencing processes in human cell 
lines. The depletion of TRBP by RNAi causes defects of these pathways in human 
cells [72, 140]. TRBP protein is composed of three dsRBDs, but only the second 
domain has significant RNA binding capacity (although some reports showed the 
weak RNA binding activity in the first domain) [141, 142]. The third RBD provides a 
protein binding platform to interact with Dicer helicase [93, 143, 144], and recruits 
Dicer complex to Ago2 for miRNA processing and gene silencing events [72]. 
Although Argonautes and the bound small RNAs have been demonstrated as the 
minimal functional unit of holo-RISC complex in vitro [66, 67], Dicer-TRBP 
complex, which functions not only in miRNA processing but also as a platform for 
RISC assembly, is also critical to RISC behavior. Dicer-TRBP complex together with 
Argonaute 2 is currently regarded as the catalytic engine of the RISC. 
Kiaa1093 (also termed as TNRC6B) is another component in Dicer-AGO 
effectors complex [77]. Kiaa1093 is 175 kDa and it is a homolog of GW182, which is 
  
 
a putative marker of p bodies. But kiaa1093’s function is poorly characterized. It was 
reported that kiaa1093 is a component of the miRNA pathway guiding mRNA 
destabilization processes and is required for miRNA-guided mRNA cleavage in vivo 
[73, 77]. When kiaa1093 is depleted, at least 30 mRNAs are significantly stabilized 
[77]. It was also reported that although kiaa1093 localized at p bodies in cytoplasm 
[77], after treatment with leptomycin B (LMB), an inhibitor of Crm1-dependent 
nuclear export, substantial kiaa1093 accumulates in the nucleus, which suggested that 
this P-body protein kiaa1093 actively shuttles between the cytoplasm and nucleus 
[83]. In contrast, its paralog GW182 does not accumulate in the nucleus upon LMB 
treatment [83]. This raises the possibility that kiaa1093 may have as yet unexplored 
nuclear and/or nuclear export functions. Although kiaa1093 is in the AGO containing 
complex and co-localized at p bodies, it has not been linked to AGO function thus far 
[73, 77].  
So far, two domains have been identified in Kiaa1093. One is known as AGO 
proteins binding site, termed as ‘AGO hook’, a Gly-Trp (GW) or Trp-Gly (WG) 
repeats [83]. The other is RRM at the C-terminal of kiaa1093 sequence.  
RRM is one of the most abundant protein domains in eukaryotes (present 
about 0.5-1% of in human genes) presenting a typical β1-α1-β2-β3-α2-β4 topology 
[145]. There are conserved RNP1 and RNP2 at β3 and β1 strands respectively in 
many RRMs. The four β strands together form a platform for RNA recognition and 
interaction. Both biochemical and structural studies indicate that RRM does not only 
play roles in RNA recognition but also in protein-protein interaction. And many 
proteins containing RRM have been demonstrated to be involved in post 
  
 
transcriptional gene expression [145]. Derived from general RRMs’ biological 
functions, it is possible that kiaa1093 RRM interacts with specific RNAs and/or 
proteins and play some roles in the RISC functions. 
In this chapter we report a crystal structure of kiaa1093’s RRM, which shows 
that kiaa1093 RRM adopts a non-canonical RRM fold. Kiaa1093 contains an extra C-
terminal α helix which presents in few known RRMs and which blocks the putative 
RNA binding platform, i.e. the four β-sheet surface. We hypothesize that the kiaa1093 
RRM may not be a RNA binding domain but a protein binding domain due to the 
interfering C-terminal α helix. We have demonstrated the hypothesis and establish the 
physical association between kiaa1093 RRM and TRBP in vitro by both pull-down 
assay and ITC experiments. Notably, our results indicate that, although kiaa1093 
RRM itself does not bind to siRNA, kiaa1093 RRM enhance TRBP’s small RNA 
interaction affinity.  
2. Results 
2.1. Bioinformatics analysis of kiaa1093 RRM  
Bioinformatics analysis of kiaa1093 only identifies two domains (Figure. 3-
1A). One is the ‘AGO hook’ (943-1014), which has been confirmed as Argonautes’ 
binding site. The other is the C-terminal RRM (1648-1720), with unknown function. 
The secondary structural prediction by Porter (http://distill.ucd.ie/porter/) shows 
kiaa1093 present a topology of β1-α1-β2-β3-α2-β4-α3. Compared with the typical 
RRMs topology of ‘β1-α1-β2-β3-α2-β4’, kiaa1093 RRM contains an extra C-terminal 
  
 
α-helix (Figure. 3-1B). On the hints of typical RRMs’ function and the secondary 
structure prediction, kiaa1093 RRM might be involved into either protein-RNA 
interaction or protein-protein interaction.  
2.2. Native and Semet- RRM proteins purification and crystallization 
The kiaa1093 RRM is cloned into HIS/SUMO-tagged expression vector pET28M, 
with the protein next expressed in E.coil and subsequently purified to homogeneity. 
The HIS/SUMO tag is then removed by ULP-1 protease. The native RRM is 











Figure 3-1.  Bioinformatics analysis of kiaa1093 
A. Cartoon representation of kiaa1093 domain arrangements 
AGO hook (943-1014), has been confirmed as an Argonautes binding site whereas the 
function of C-terminal RNA recognition motif (RRM) (1648-1720) is still kept unknown. 
Kiaa1093 RRM may be serving as RNA binding domain or a protein binding site.  
B. The secondary structural prediction of kiaa1093 RRM 
Arrows with green color represent β strand structure, whereas the rectangles with pink color 
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9% PEG 4000, 7.5% EG, 0.1% β-OG. The Semet-RRM is prepared as described 
previously (Figure. 3-2A and 3-2B). But crystallization condition for the Semet-RRM 
varies a lot from the native one. The Semet-RRM crystals grow at the present of 
(100mM Tris (pH 7.5), 0.7 M CaCl2, 14% PEG 4K, 7.5% EG, and 0.1% β-OG 
(Figure. 3-2C and 3-2D).  
2.3. Data collection and structure determination  
There are two batches of crystals are sent for data collection and structure 
determination. The first one with low resolution (2.5 Å) is for structure determination. 
The second set with higher resolution (1.9 Å) is used for refinement.  
For data collection, crystals are flash frozen (100K) in the above well solution 
supplemented with 30% glycerol. A total of 360 frames of 1° oscillation are collected 
for each crystal. The data are collected on beamline X12C at the National Synchrotron 
Light Source at Brookhaven National Laboratory and are processed by HKL2000 
(www.hkl-xray.com). The crystals belong to space group P6, with crystallographic 
statistics parameters listed in Table 3-1. The crystal structure of kiaa1093 is 
determined by single wavelength anomalous diffraction (SAD) using 
SOLVE/RESOLVE (http://www.solve.lanl.gov) and the SAD phase is calculated and 
improved by density modification assuming a solvent content of 48% using the 
SHARP program (http://www.globalphasing.com). The model is built by using the 
program O (http://xray.bmc.uu.se/alwyn) and refined using REFMAC/CCP4 
(www.ccp4.ac.uk) with the crystallographic statistics listed in Table 3-1. The R-free 












Figure 3-2. Protein purification and crystallization 
A. Purification of native RRM. 
B. Crystals of Native RRM (20°C) at the present of 100mM MES (6.0), 0.6 M CaCl2, 9% 
PEG 4000. 
C. Purification of SeMet-RRM. 
D. Crystals of semet- RRM (4°C) at the present of 100mM Tris (pH 7.5), 0.7 M CaCl2, 14% 










2.4. Overview structure of RRM domain 
The crystallographic statistical analysis of the kiaa1093 RRM structure is 
reported in Table 3-1. The kiaa1093 RRM adopts an overall RRM fold (Figure. 3-3C). 
Kiaa1093 RRM contains five β sheets and three α helixes. The four-stranded anti-
parallel β- sheets are constituted by β strands: β1 (residues 2-7), β2 (29-34), β3 (38-
44), and β5 (65-71), with a very small β4 (59-62) between α2 and β5; three α helices, 
α1 (residues 15-25) and α2 (residues 47-57), are perpendicular to each other and 
packed on one side of the β-sheet, and  α3 (74-79) at C-termini (Figure. 3-3C). 
Compared with typical RRM as shown in Figure 3-3D (take PTB RRM1 as example 
[147]), kiaa1093 RRM contains a particularly extended helix α3 comprising 6 amino 
acids and blocking the four-stranded anti-parallel β- sheet surface, which serves as an 
RNA binding interface in PTB RRM1 (Figure. 3-3C and D).   
2.5. Kiaa1093 RRM has no interaction with small RNA or DNA  
On the basis of structural information, kiaa1093 harbors an extra C-terminal α 
helix, which has unknown function and blocks the putative RNA binding surface. 
Interestingly, RRM of p14 (denoted p14 hereafter), subunit of the essential splicing 
factor 3b (SF3b155), has similar structure to kiaa1093 RRM, which also comprises a 
non-canonical RRM topology with an extra C-terminal α helix [146]. It was reported 
that p14 RRM is a protein binding domain and has very weak interaction with RNA, 
which drives us to hypothesize that kiaa1093 RRM might compromise RNA binding 
affinity.  We performed EMSA experiment to investigate RRM’s RNA binding 
affinity. The 21nt single stranded RNA (21ss), 19nt double stranded RNA with 3’ 2-nt 
overhang (21siRNA), 23nt single stranded DNA (23ssDNA) and 25nt single stranded 







Data collection   
 Low resolution (SAD) High resolution 
Space group P6 P6 
Cell dimensions a, b, c (Å) 76.805, 76.805,52.511, 90, 
90, 120 
76.394, 76.394, 52.118, 
90, 90, 120 
Wavelength (Å) 0.9797 1.1 
Resolution (Å) a 50~2.5 (2.59~2.5) 50~1.9 (1.97~1.90) 
Rsym (%) a 10.6(86.4) 7.1(50.4) 
I/　(I) 30.7(3.4) 60.0(8.3) 
Completeness (%) a 99.9(100) 100(100) 
Redundancy 11.5(11.6) 22.4(22.2) 
Initial Figure of Merit 0.3 0.3 
Refinement  
Resolution (Å)                          50~1.9 
No. reflections  13116 
Rwork (Rfree) (%)  19.7(22.6) 
No. atoms   
Protein  1310 
Water  158 
B-factors (Å2)   
Protein  38.0 
Water  35.8 
R.m.s. deviations   
Bond lengths (Å)  0.1 
Bond angles (º)  1.175 
% favored (allowed) 
In Ramachandran plot 
 94.0(6.0) 
a Values for the highest-resolution shell are in parentheses. 
 







Figure 3-3. Structure determination of kiaa1093 RRM 
A. Diffraction pattern of kiaa1093 RRM 
B. Experimental electron density map of kiaa1093 RRM by SAD phasing 
C. Structure determination of RRM from kiaa1093. The extra C-terminal α helix is 
highlighted in red. 








as ligands. The protein samples are shown in Figure 3-4A and B. The free form small 
RNAs and DNAs are shown in Figure 3-4C. The EMSA results show that the wild 
type kiaa1093 RRM (as shown in Figure 3-4D: lane 1, 3, 5, and 7) does not bind to 
any of the 21ssRNA, 21siRNA, 23ssDNA, and 25ssDNA, respectively. In order to 
investigate the C-terminal α helix roles in the RNA interaction events, a mutant of 
kiaa1093 RRM by deletion of the extra C-terminal α helix (residues 74-79) (denoted 
as RRM ∆ C-terminal α helix) is generated. However, EMSA result shows that even 
after the removal of this interfering α3 helix which consequently enables the exposure 
of the RNA interacting surface in most possibility, kiaa1093 RRM still has no 
interaction with the mentioned oligos (as shown in Figure 3-4D: lane 2, 4, 6, and 8). 
We therefore hypothesize this kiaa1093 RRM may not be a RNA binding domain.                          
2.6. Bioinformatics analysis of RRM binding partners 
It was reported that this p14 RRM is a protein binding domain and has very 
weak interaction with RNA. Interestingly, despite of the interfering C-terminal α 
helix, the protein binding surface is still localized at the four beta strands surface. We 
blast the central binding epitope with the sequence of LDAMFPEGYKVL of 
SF3b155, the binding partner of p14, and found that the linker region between TRBP 
D1 and D2 has sequence similarity with this central binding epitope (Figure. 3-5A).  
2.7. RRM interacts with TRBP  








Figure 3‐4. Both RRM and RRM Δ C- α helix have no interaction with the selected RNA and 
DNA 
A. Purification of SUMO, SUMO-RRM, and RRM. 
B: Purification of RRM Δ C- terminal α helix. 
C: Free small RNAs and DNAs. 
















  On the basis of bioinformatics analysis, we found that the linker region 
between TRBP D1 and D2 has amino acid sequence similarity with the RRM binding 
epitope of SF3b155, the partner of p14. Therefore we hypothesize that TRBP might 
be one of kiaa1093 binding partners via RRM domain (Figure. 3-5B). Although both 
TRBP and Kiaa1093 present in human AGO-containing protein complexes, the 
relationship between the two proteins has not been addressed yet. In order to 
investigate the relationship between TRBP and kiaa1093, we prepare the proteins of 
TRBP D1 (denoted as D1), D2, D1+2, and full length with C-terminal fusion Flag tag 
(as shown in Figure. 3-6A). Unfortunately D3 is not available due to the insolubility. 
We also synthesize the peptide of the linker region between D1 and D2.  
TRBP domains with C-terminal Flag tag (2.5µmol) are applied to Anti-FLAG 
Affinity beads (20 µl) (Sigma). After 3 hours’ incubation at 4°C with rotation, the 
non-specific binding proteins are washed out and followed by another round of 
incubation with 10 µmol SUMO-RRM and SUMO respectively (SUMO tag is taken 
as negative control), respectively. In the pull down experiment, we find that kiaa1093 
RRM interact with TRBP mainly through the first domain (shown in Figure. 3-6 B), 
whereas, the linker region between TRBP D1 and D2 shows no interaction with 
kiaa1093 RRM (data not shown) through the ITC experiment. In Figure 3-6B, Lane 1 
to Lane 4 show sequentially the binding affinity of TRBP D1, D2, D1+2, and full length 
with kiaa1093 RRM, whereas no signal is detected in the control reactions (Lane 5 to 
lane 8). D1 and D1+2 show the higher binding affinity with kiaa1093 RRM than that of 
full length TRBP. D2 has the lowest binding affinity with kiaa1093 RRM. This result 
provides the evidence that kiaa1093 RRM interacts with TRBP in vitro mainly 











Figure 3‐5. Bioinformatics analysis of TRBP and its domain arrangement.  
A. Blast of central binding epitope of p14 RRM’s partner and TRBP.   
B. The Cartoon representation of TRBP domains arrangement 
D2 present major RNA binding capacity of TRBP. And D3 interacts with Dicer helicase, 
whereas D1 is poorly understood. 
TRBP 





SF3b155 binding epitope 






We also perform ITC experiments to confirm the results derived from the pull down 
assay. The ITC results are accordance with the pull down data (Figure. 3-6C and 
Table. 3-2). D1 has the highest binding affinity with kiaa1093 RRM. And  both D2 and 
full length show ten times less binding affinity with kiaa1093 RRM than D1, whereas 
the D1+2 shows 1.5 times less binding affinity (Table. 3-2).  
2.7.2. RRM’s C-terminal α-helix plays important role in the interaction between 
TRBP and RRM. 
 As we discussed before, the C-terminal α helix blocks the RNA binding 
surface derived from the kiaa1093 RRM structural information. However, as to p14, 
RRM, it was reported that although p14 has a similar interfering C-terminal α helix, 
the binding surface between p14 and SF3b155 is still at the four β-sheet surface [146]. 
Considering the similarity between kiaa1093 RRM and p14 structure, we perform pull 
down assay to investigate the C-terminal α helix’s role in this protein-protein binding 
event. Interestingly, the pull down results suggest that the binding affinity between 
RRM ∆ C-terminal α helix and TRBP domain dramatically decreased (Figure. 3-7, 
lane 5-8) compared with the wild type kiaa1093 RRM (Figure. 3-7, lane 1-4). This 
data indicate that extra C-terminal α helix plays very important roles to bridge the 
interaction between kiaa1093’s RRM and TRBP domains. 
2.7.3. The kiaa1093 RRM enhances the binding affinity between TRBP D1+2 and 
21siRNA. 
TRBP has been identified as an RNA binding protein which is composed of three 
RBDs, but only D2 has higher binding affinity with small RNA. This conclusion is 
also confirmed by our EMSA data. D2 has highest binding affinity with 21siRNA, 






Figure 3‐6. Physical association of TRBP and kiaa1093 RRM 
A. Purification of TRBP domains. 
B. Pull down assay of TRBP domains and kiaa1093 RRM. Lane 1 to 4 show the interaction of 
kiaa1093 RRM and TRBP D1, D2, D 1+2, and full length sequentially. Lane 5 to 8 show that 
SUMO, as negative control, has no interaction with TRBP domains.  


























Figure 3‐7. C-terminal α helix plays important role in the interaction of kiaa1093 RRM 
and TRBP. Lane 5 to 8 show that the binding affinity between TRBP and kiaa1093 RRM 
decreases significantly after the removal of C-terminal α helix, compared with the wile type 




D1+2’s RNA binding affinity is much lower than that of D2, and even lower than that 
of D1. And full length of TRBP almost has no interaction with siRNA. In order to 
investigate functional roles of kiaa1093 and TRBP’s interaction, we next introduce 
kiaa1093 to the TRBP domains and siRNA complex. As shown in Figure 3-8 B, D1 
has very weak binding with 21siRNA and kiaa1093 RRM almost has no effect on the 
D1’s binding with the siRNA.  Lane 1 is free siRNA. Lane 2 is D1 with 21siRNA and 
shown very weak interaction inbetween, which is same as that shown in Figure 3-8 A. 
Lane 3 is the RRM with 21siRNA and no retardant band is detected. Lane 4 to lane 8 
shows the binding affinity between D1 and 21siRNA has no significant changes with 
the increasing amount of kiaa1093 RRM. Therefore the addition of kiaa1093 RRM is 
not helpful for siRNA and D1 interaction. Moreover, although D1 interacts with both 
RRM and siRNA, the protein binding site and the RNA binding site are not 
competitive. 
Figure 3-8C shows the effects of kiaa1093 RRM on D2 and small RNA 
interaction.   Lane 1 and 2 are negative controls of free siRNA and RRM with siRNA, 
from which no retardant bands are detected.  Lane 3 is D2 with 21siRNA which shows 
higher binding affinity. Lane 4 to lane 9 shows no obvious changes of D2 RNA 
binding affinity with the increasing amount of RRM. Similar to the result of D1, 
kiaa1093 RRM has little influence on D2 and siRNA interaction.  
Figure 3-8D shows the effects of kiaa1093 RRM on D1+2 and full length 
TRBP binding with siRNA. Lane 1 and 2 are free 21siRNA and RRM/siRNA, setting 
as negative controls as before. Lane 3 shows very weak binging between D1+2 and 
siNRA, whereas with the present of kiaa1093 RRM (Lane 4 and lane 5), the D1+2’s 






















Figure 3-8. The kiaa1093 RRM may have effects on TRBP RNA binding capacity 
A. TRBP is a RNA bind protein and it binds with 21siRNA at various domains with different 
affinities. 
B. kiaa1093 RRM has less effect on RNA binding capacity of D1.  
C. kiaa1093 RRM has no effect on RNA binding capacity of D2.  
D. kiaa1093 RM has effects on TRBP D1+2’s RNA binding capacity whereas no influence on 
full length of TRBP 






7-10), the binding affinity with siRNA is too low to be detected with or without 
present of kiaa1093 RRM. 
In order to confirm the kiaa1093 RRM’s effects on D1+2’ and RNA interaction, 
we perform an experiment to investigate the relationship between the dose of the 
kiaa1093 RRM and the magnitude of the graded effect (Figure. 3-8E). It is 
demonstrated that, D1+2’s RNA bind affinity is enhanced greatly with increase amount 
of kiaa1093 RRM.   
3. Discussion 
RRMs are abundant and ancient folds. Although the structure of these domains 
is highly conserved with β1-α1-β2-β3-α2-β4 topology, differences in recognition 
various partners reflecting the remarkable adaptability of this kind of domains. Over 
the last few years, biochemical and structural studies have shown that the RRMs not 
only functions as RNA binding sites, but also mediate protein-protein interaction. In 
addition to RRM/RNA complex structures, the structures of RRMs in complex with 
various proteins or domains are also available. Analysis of these structures shows that 
protein recognition by RRM domains is very diverse without general mechanism.  
In this study, we report a crystal structure of kiaa1093 RRM. We observe that 
besides the RRMs’ canonical β1-α1-β2-β3-α2-β4 topology, kiaa1093 RRM also 
harbors an additional C-terminal α helix, which is only present in few of known 
RRMs. This extra structure blocks the four-stranded anti-parallel-β sheets and 
consequently the putative RNP1 and RNP2, the key motifs which are contributed to 
RNA interaction. Therefore it is possible that the RNA binding ability of kiaa1093 
RRM is compromised by the interfering additional C-terminal α helix, which is 




RRM still has no interaction with small RNAs or DNA (Figure. 3-4D). This result 
drives us to hypothesize that kiaa1093 RRM might function as a protein binding 
domain, although it is still hard to draw such a conclusion that Kiaa1093 RRM is not 
RNA binding motif, because it was reported that some RRMs recognize RNA in 
sequence-specific mode and it does not rule out the possibility that the oligos selected 
in this study are not suitable substrates for kiaa1093 RRM. 
We have proved that kiaa1093 RRM is a protein binding domain and 
established the direct interaction between kiaa1093 RRM and TRBP domain by in 
vitro affinity binding assay (Figure. 3-6B). This physical association is further 
verified by ITC results (Figure. 3-6C and Table 3-2). The interaction between TRBP 
and kiaa1093 RRM is mainly mediated by TRBP D1 (Figure. 3-6B, 3-6C and Table. 
3-2). Interestingly, the kiaa1093 RRM C-terminal α helix plays very important role in 
the interaction with TRBP. After removal of this extra helix, the binding affinity 
between TRBP and kiaa1093 decreased significantly (Figure. 3-7).  
Finally we provide evidence that although kiaa1093 RRM itself has no 
interaction with siRNA, it greatly enhances the RNA binding affinity of TRBP D1+2 
with siRNA, but it has no significant effects on D1, D2, and full length TRBP.  
These results might be explained by the following diagrams (Figure. 3-9). As 
shown in Figure 3-9 A, TRBP domains have individual duties via binding different 
partners derived from literatures and our data (Figure.3-6B, 3-6C, 3-8A, and Table. 3-
2) [72]. It is D2 that is mainly responsible for RNA interaction. But this RNA binding 
site might be always blocked by D1 and/or D3 in free form of TRBP, which is 
illuminated by the EMSA data that TRBP D1+2 and Full length TRBP has very low 
RNA binding activity (Figure. 3-8A and 3-9B). Illuminated by our results, the 




change of TRBP D1+2, so that RNA binding site on D2 is exposed, which 
correspondingly results in the enhanced RNA binding activity (Figure, 3-8D, 3-8E, 
and 3-9C).  
The phenomenon that full length of TRBP has still no interaction with siRNA 
at the present of kiaa1093 RRM might result from the following reasons. Only the 
association of kiaa1093 RRM is not adequate to expose D2 in full length TRBP, 
because D3 may be another factor to block with D2/RNA interaction (Figure. 3-9D 
and 3-8E). It is possible that both kiaa1093 and Dicer are required for TRBP to 
interact with siRNA in vivo (Figure.3-9E), however we do not have direct evidence to 
support this hypothesis.  
Our findings suggest, in the TRBP/Dicer complex, kiaa1093 may serve as a 
scaffolding protein and interact with TRBP via its C-terminal RRM domain to 
stabilize and strengthen the TRBP/siRNA interaction. The TRBP/kiaa1093 interacts 






Figure 3‐9.The hypotheses of binding mode of TRBP, kiaa1093RRM, and Dicer  
A. Binding mode of TRBP Domains with protein or RNA 
1. Cartoon presentation of arrangement of TRBP domains 
2. Cartoon model of the  interaction between D1 and kiaa1093 RRM 
3. Cartoon model of the interaction between D2 and small RNA 














B. Binding mode of TRBP D1+2 and full length with small RNA without kiaa1093 RRM 
involvement.  D1 and D3 may interfere with D2 RNA binding capacity. 
C. Binding mode of TRBP D1+2/RRM/siRNA. The presence of kiaa1093 RRM may change 


























































D. Binding mode of TRBP (full)/RRM/siRNA.  
The kiaa1093 RRM changes the full of TRBP’s confirmation. However D3 still interferes 
















E. Binding mode of TRBP (full)/RRM/siRNA.  
The kiaa1093 RRM and Dicer helicase change the full of TRBP’s confirmation and enhance 










































Chapter Four: Structural basis for RNA-silencing 
suppression by Tomato aspermy virus protein 2b 
Summary  
The 2b proteins encoded by cucumovirus act as PTGS suppressors to counter host 
defense during infection. Here we report a crystal complex structure of Tomato 
aspermy virus 2b (TAV2b) bound to a 19 bp siRNA duplex. TAV2b adopts an all α-
helix structures and forms a homodimer to measure siRNA duplex in a length-
preference mode. TAV2b has a pair of hook-like structures to recognize 
simultaneously two α-helical turns of A-form RNA duplex by fitting its α-helix 
backbone into two adjacent major grooves of siRNA duplex. The conserved π-
stackings between tryptophan and the 5’-terminal base of siRNA duplex from both 
ends enhance the recognition. Dimerized TAV2b further forms a tetramer through the 
conserved leucine-zipper-like motif at the N-terminal α-helix. Biochemical 
experiments’ results suggest that TAV2b might interfere with the PTGS pathway by 
directly binding to siRNA. 
1. Introduction  
RNA silencing is a small regulatory RNA-mediated biological process 
conserved in plants and animals. In plants, RNA silencing is believed to be an ancient 
immune response triggered against viral dsRNAs [11]. In the response to host defense 
via RNA silencing, viruses encode a wide range of suppressors with different 
sequences, motifs and structures to counter RNA silencing by targeting different 




CMV2b is one of the first suppressors of RNA silencing. Previously, it was 
reported that CMV2b from the FNY strain interacts directly with Arabidopsis 
Argonaute1 (AGO1) both in vitro and in vivo to inhibit RISC-mediated mRNA 
cleavage [71]. Recently, CMV2b from the CM95R strain was reported to bind with 
the in vitro synthesized siRNAs, indicating that CMV2b might also suppress RNA 
silencing by sequestering siRNAs [148]. Similar to CMV, TAV is also a member of 
the cucumovirus family. Moreover, 2b protein encoded by TAV is an RNA silencing 
suppressor as well [149]. However, TAV2b and CMV2b vary widely in RNA-
silencing suppression and resulting phenotype despite of the homologues sequence.  
To define the binding mode of TAV2b-dsRNA, we determine the TAV2b (1-
69) structure bound to a 19 bp siRNA at 2.8Å (TAV2b refers to TAV2b (1-69) 
hereafter). The complex structure shows that TAV2b interacts with a bound siRNA 
duplex through the deeply buried half of its protein segment inside the major groove 
of the siRNA duplex. TAV2b forms a pair of hook-like dimers to recognize the 
siRNA duplex in a sequence-independent and length-preference manner. And several 
key residues play crucial roles in TAV2b suppressing RNA silencing.  
2. Results 
2.1. TAV2b is a small dsRNA-binding protein 
EMSA data shows that TAV2b is a small RNA binding protein (Figure 4-1A). 
Lane 1 is positive control of p19-siRNA. Lane 2 and lane 3 shows that TAV2b binds 
to both 21siRNA (19bp) and 32siRNA (30bp) with high affinity, whereas binding 
activity with 26 dsDNA is very weak as shown in lane 4. Figure 4-1B shows free 











Figure 4‐1. TAV2b is a dsRNA binding protein. 
A. TAV2b interacts with 21 and 32siRNA with high binding affinity. But binding affinity 
with dsDNA is much lower.  P19 and 21siRNA reaction is setting as positive control. 




2.2. TAV2b forms dimers in solution 
TAV2b forms dimers in solution in the absence of dsRNA, which is confirmed by 
denatured SDS PAGE gel (Figure. 4-2A) and analytical gel filtration (Figure. 4-2B.  
and 4-2C). As mentioned before, the molecular weight of TAV2b (1-69) used in this 
study is around 7.5 kDa. But there is a single band with the size of around 15 kDa on 
SDS PAGE gel, suggests that TAV2b might form dimer in solution (Figure. 4-2A).      
 The dimeric TAV2b is extremely stable even after treated with SDS loading 
dye and boiled for 5-7 minutes (Figure. 4-2A). When TAV2b is cross-linked by 
Ethylene glycolbis (EGS), we observe different forms of polymers and one of the 
most distinguished band is around 30kDa, suggesting tetramer formation of TAV2b 
(as shown in Figure. 4-2A lane 1-4). After that, we test the polymerization of TAV2b 
under native condition by analytical gel filtration. Analytical gel filtration data 
indicates that TAV2b forms dimers (Figure. 4-2C), which is agreement with the result 
under denature condition (Figure. 4-2A). Interestingly, at the present of 21siRNA, the 
TAV2b-dsRNA complex migrates as a single peak around 60 kDa, which corresponds 
to a TAV2b-RNA tetramer (i.e. four TAV2b molecules and two siRNA duplexes, the 
MW of siRNA duplex is close to a 10kDa protein) (Figure. 4-2B and 4-C). 
2.3. Protein crystallization, data collection, and structural determination 
(This part of work is done by Chen Hongying) 
The TAV2b gene is cloned into pET28b vector with a C-terminal HIS tag, with 
the protein next expressed in E. coil and subsequently purified to homogeneity. SeMet 
TAV2b is prepared as described before. TAV2b protein and siRNA duplex are co-
crystallized at 20°C under the condition of 25% PEG 1500, 1.0M ammonium formate, 
























Figure 4‐2. TAV2b forms tetramer in solution. 
A. TAV2b forms tetramer in solution. SDS-PAGE gel showed that TAV2b formed 
tetramer (indicated by a star) in solution when treated with the increasing amount of 
EGS (lane 2 to lane5), whereas TAV2b LILM mutant resisted to form tetramer under 
the same condition.  
B. Analytical gel filtration assays of TAV2b tetramerization.  
C. Molecular weight calculation aligned with the molecular standard. Free TAV2b and 
LILM mut has similar molecular size. TAV2b/siRNA complex is around 60kDa, 






reservoir solution. Crystals are flash frozen (100 K) in the above reservoir solution 
supplemented with 30% glycerol. A two-wavelength data set is collected on a SeMet 
crystal and processed by HKL2000 (www.hkl-xray.com). The structure is determined 
by multiwavelength anomalous dispersion using SHARP (www.globalphasing.com).  
The model is built by using the program O (http://xray.bmc.uu.se/alwyn) and refined 
using REFMAC/CCP4 (www.ccp4.ac.uk) with the crystallographic statistics listed in 
Table 4-1.  
The model comprises residues 5-58. Disordered regions, including N-terminal 
tail 1-4, C-terminal tail 59-69 and 3’ 2-nt overhangs of siRNA, are not included in the 
model. The coordinates and the structure factors have been deposited in Protein Data 
Bank with accession code 2ZI0. 
2.4. Overview of the TAV2b-siRNA duplex complex structure  
The structure of the complex shows that TAV2b is composed of two long α-
helices which are connected by a conserved short linker with half of its protein 
segment buried within the major groove of the siRNA duplex. TAV2b forms a dimer 
and the dimerized TAV2b has a pair of hook-like structures to recognize and bind to 
the siRNA duplex at its major groove in a length-preference manner instead of length-
dependent or sequence-dependent modes (Figure.4-3B and 4-3C). The N-terminal α1 
helix and the C-terminal α2 helix are connected by a highly conserved linking region 
and form a 120° angle (as shown in Figure. 4-3A and highlighted in yellow). Also, the 
N-terminal α1 helix and siRNA helical axis form a 120° angle to maximize the 














is almost parallel to the siRNA helical axis. Interestingly, the dimerized TAV2b 
further forms tetramer by means of a conserved leucine-zipper-like motif (residues 
Leu 8, Ile 11, Leu 15, and Met 18) at its N-terminal α1-helix (Figure. 4-2B, 4-2C and 
4-3D).   
2.5. Key residues at both RNA-protein interface and protein-protein 
interface of TAV2b 
The TAV2b dimer buries 1,495Å2 of the total solvent-accessible area of the 
bound siRNA duplex. The dimerized TAV2b recognizes two continuous helical turns 
formed  by the 21 nt (19 bp) siRNA duplex by fitting the protein backbones into the 
major grooves (Figure. 4-3B, 4-3C, and 4-3D). And the RNA-protein binding 
interface are clustered continuously along major groove of the bound siRNA duplex 
(Figure. 4-4A and 4-4B).  
There are several groups of key residues which are critical to either RNA-
protein interaction or protein-protein interaction (listed in Table 4-2). One group is 
leucine-zipper-like motif (residues Leu 8, Ile 11, Leu 15 and Met 18) at its N-terminal 
α1 helix which mediates the dimerized TAV2b to form a tetramer (Figure. 4-3D, 
Table. 4-2). In order to confirm the roles of leucine-zipper-like motif in the 
tetramerization of TAV2b, the mutant with the alanine substitutions on this motif is 
generated (referred as LILM Mut). In agreement with the structural information, the 
LILM Mut shows very weak oligomerization after cross-linked by EGS (Figure. 4-
2A, lane 6-9). Moreover, at the present of siRNA, the LILM Mut-siRNA complex 
migrates at around 30kDa instead of 60kDa as shown in analytical gel filtration data 











































Figure 4-3. Overview of TAV2b/siRNA structure 
A. Sequence alignment of 2b proteins from the cucumovirus family. TAV2b protein 
comprising residues 1–69 is used in crystallization. Secondary structural prediction is shown 
on the top. Dashed lines denote disordered residues. Conserved residues are shaded in cyan 
(80% conservation) and green (60% conservation), whereas essentially invariant residues are 
shaded in yellow. 
B. TAV2b dimers are presented in a cartoon view and colored in orange and magenta, 
whereas siRNA duplexes are represented in a surface view and colored in cyan and green, 
respectively. 
C.TAV2b dimers are presented in an electrostatic surface view with blue and red colors 
corresponding to positively and negatively charged patches, respectively, whereas siRNA 
duplexes are presented in a cartoon view and colored in cyan and green, respectively. 
D. Molecular details of protein–protein interactions. Cartoon representation of TAV2b/RNA 




motif disrupt the tetramerization of TAV2b. However, mutations of LILM have little 
influence on TAV2b RNA binding capacity (Figure. 4-5B and Table 4-3).  
At the RNA-protein binding interface, there are a patch of positively charged 
residues, including Arg 26, His 29, Asn 32, Arg 33, and Arg 36, from one surface of 
the TAV2b monomer, form hydrogen bonds and electrostatic interactions with both 
strands of the dsRNA (Figure. 4-4A, 4-4B, and Table. 4-2). Another patch of 
invariable residues, including Lys 39, Ser 40, Pro 41, Ser 42, and Glu 43 continuously 
form hydrogen bonds along the major groove of siRNA (Figure. 4-4A, 4-4B, and 
Table. 4-2).   
Within the short link connecting the two a-helices, there are two key residues. 
Residue His 38 further stabilizes the protein-RNA interactions by forming hydrogen 
bonds with the phosphate from the dsRNA, whereas residue Gly 37 helps to kink the 
two long helical axes of TAV2b at an orientation of 120° to facilitate further protein-
RNA interactions (Figure. 4-4A and 4-4B). Interestingly, both Gly 37 and His 38 are 
conserved residues among the 2b family of proteins, with some exceptions: Cys 
substitution of Gly or Tyr substitution of His (Figure.4-3A). Nevertheless, the 
structural features of Cys and Gly (small side chain) or Tyr and His (aromatic ring 
and hydrogen bond) are conserved.   
One more invariable residue, Pro 41, locates at the first residue of the C-
terminal α2 helix, which rotates 120° away from the N-terminal α1 helix (Figure. 4-
4A and 4-4B). The van der Waals interactions between the aromatic ring of Pro 41 
and the phosphate moiety of uracil 15 (U15), together with the hydrogen bonds 
formed between its invariable neighbor residues Ser 40/Ser 42 and the phosphorus 






















Figure 4‐4. Characterization of the RNA–protein interface and protein–protein interface 
of TAV2b  
A. Schematic representation of RNA–protein interactions.  
Dashed lines, hydrogen bonds with the phosphate backbone; solid arrows, van der Waals 
contacts. The invariable residues are colored in red, whereas the relatively conserved residues 
are colored in yellow.  
B. Molecular details of RNA–protein interactions.  
One TAV2b/siRNA duplex represented in a cartoon view is shown for clarity. One TAV2b 
monomer is colored in blue and another in green. The invariable residues are colored in red, 











Key residues Structural characters 
Leu 8; Ile 11; Leu 15; Met 18; leucine-zipper-like motif mediates the 
formation of tetramer 
Arg 28; His 29; nuclear localization signals (NLS) 
Arg 26; His 29; Asn 32;  Arg 33; 
Arg 36; 
Positively charged residues form 
hydrogen bonds and electrostatic bonds 
with both strands of the siRNA 
Lys 39; Ser 40; Pro 41; Ser 42; Glu 
43; 
residues form hydrogen bonds along the 
major groove of siRNA 
His 38; Gly 37; residues in the short link region  
connecting the two α-helices 
Trp 50; projecting from the α1 helix and recognize 
both ends of siRNA. 
 
 




4B). This structural information suggests Pro 41 is crucial to kink the protein and 
further anchor the C-terminal α2 helix on the major groove of bound siRNA. In 
accordance with the structural observation, alanine mutation on Pro 41 decreased the 
dsRNA binding affinity ten times as shown by ITC data (Figure. 4-5C and Table. 4-
3).  
Remarkably, a unique tryptophan residue (Trp 50) projecting from the middle 
part of the C-terminal α2 helix of one monomer π-stacks over the 5’ terminal base of 
the bound dsRNA from one side, whereas Trp 50 from its non-crystallographic 
symmetrical related molecule π-stacks over the 5’-terminal from the other side, 
thereby both ends of the siRNA duplex are recognized and measured by the TAV2b 
dimer (Figure. 4-4B and Table. 4-2). Although Trp 50 is relatively conserved, TAV2b 
might not strictly measure the length of siRNA duplex by this unique tryptophan 
residue. Our ITC data showed that the Trp50 Arg mutant shows only two times less 
binding affinity, whereas the Trp50 Ala mutant shows five times less binding affinity 
(Figure. 4-5E, 4-5F and Table. 4-3).   
On the basis of bioinformatics prediction, TAV2b contains a nuclear location 
signal (NLS), which is also encoded by CMV2b. And this functional arginine-rich 
NLS in CMV2b with sequence of KRRRRR is required for the efficient suppression 
of PTGS [149]. In order to confirm whether NLS is crucial for TAV2b RNA binding 
capacity, we generate mutations on the residues of Arg 28 and His 29, which are 
localized at the NLS region of TAV2b [149]. RNA binding assay shows that the 
mutations on the Arg 28 and His 29, decrease the RNA binding affinity by ten times 






Figure 4‐5. ITC data of TAV2b and its mutants binding with 21nt siRNA duplex.  
Raw titration data and integrated heat measurements are shown in the upper and lower plots, 
respectively. The Ka and stoichiometry numbers (n) obtained by fitting a standard two-
interaction site model are reported with the associated s.d. determined by nonlinear least-
squares analysis. The stoichiometry number automatically picked by computer analysis was 
varied from 0.49 to 0.59. The Ka value was further recalculated by the fixation of n=0.5 
supported by crystal structure.  
A. siRNA duplex titrated into TAV2b WT. 
B. siRNA duplex titrated into TAV2b LILM mutant. 
C. siRNA duplex titrated into TAV2b P41A mutant. 
D. siRNA duplex titrated into TAV2b RH mutant. 
E. siRNA duplex titrated into TAV2b W50R mutant. 
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by the introduction of mutations might result in weak RNA-silencing suppression 
ability.          
2.6. TAV2b suppresses RNA silencing 
To test whether these key residues involved in either RNA-protein interaction or 
protein-protein interaction play roles in host RNA silencing suppression, we 
performed in vitro Agrobacterium co-infiltration assay in transgenic plants (16c) that 
stably express green fluorescent protein (GFP). In these transgenic plants, GFP 
silencing can be triggered by transient GFP expression by Agrobacterium infiltration, 
whereas RNA-silencing suppressors, which initiate PGTS, can rescue transient 
expression of GFP in the infiltrated regions. Our results show that transient expression 
of TAV2b suppressed GFP silencing and rescued the expression of GFP (Figure. 4-6, 
lower left spot on each leaf), similar to the suppression by the P19 (Figure. 4-6, upper 
right spot on each leaf). GFP trangene as a negative control is infiltrated alone and the 
GFP protein expression is almost completely suppressed (Figure. 4-6, upper left spot 
on each leaf). However mutations either on residue Trp 50 (Trp50 Arg and Trp50 
Ala) or residue Pro 41 (Pro41Ala), or double mutations on residues Arg 28 and His 29 
(Arg28Ala, His29Ala) result in a significant decrease in the expression level of GFP 
(Figure. 4-6, lower right spot on each leaf), which suggests that RNA-silencing 
suppression of TAV2b is destroyed after the mutations of these key residues. 
Although the mutations on Trp 50 do not have dramatic influence onTAV2b RNA 
binding capacity in vitro, the mutations have striking effect on silencing suppression, 
which suggests that Trp 50 might contribute to further network involved in the 
silencing pathway, such as the interaction with AGO1. Nevertheless, the correlations 









Figure 4‐6. RNA-silencing suppression in Nicotiana benthamiana (16c) by TAV2b 
Leaves of the 16C GFP plants are infiltrated with a Agrobacterium tumefaciens strains 
carrying 35S-GFP as negative control (upper left spot on each leaf), or together with the strain 
carrying TBSV p19 as a positive control (upper right spot on each leaf); or together with the 
strain carrying TAV2b wild type (lower left spot on each leaf); or together with the strain 
carrying TAV2b mutant (lower right spot on each leaf). The leaves are detached and 




mutants strongly suggest that TAV2b sequesters siRNA duplexes for RNA-silencing 
suppression.  
2.7. TAV2b distinguish dsRNA from dsDNA on the basis of the major 
groove structure 
On the basis of the TAV2b complex structure, TAV2b might distinguish 
dsRNA from dsDNA by measuring the width of the major groove, which is agreement 
with the EMSA result that TAV2b prefer to bind to dsRNA rather than dsDNA.  In 
order to confirm the structural observations, we perform ITC experiments to measure 
the binding affinity between TAV2b and different RNAs and DNAs.  ITC data show 
that the binding affinity between TAV2b and 26 nt dsDNA is 30 times lower than that 
between TAV2b and 21 nt dsRNA (Figure. 4-7A and Table. 4-4). And the binding 
affinity between TAV2b and 12 nt dsRNA (12 bp) is about 30 times lower (Figure. 4-
7B and Table. 4-4). Moreover, ITC data further show that TAV2b binds to 21 nt 
single-stranded RNA at sequential binding sites with a weak binding affinity (around 
100 timers lower) (as shown in Figure. 4-7C and Table. 4-4), and the binding affinity 
between TAV2b and 9 nt siRNA duplex (7 bp, no helical turn) is more than 150 times 
lower (Figure. 4-7D and Table. 4-4). These data further confirm that TAV2b prefers 
to recognize the dsRNA duplex by recognizing the helical turns.   
3. Discussion 
TAV2b recognizes siRNA duplex by a pair of hook-like structures, which 
represents a distinct mode of dsRNA binding from previous structures of suppressor-
dsRNA complexes. The TBSV p19 protein adopts an extended β-sheet surface and a 
small α-helix to form a caliper-like architecture for binding and measuring the 








Figure 4‐7. TAV2b prefers to bind to dsRNA 
A. 26nt dsDNA duplex titrated into TAV2b.  
B. 12nt dsRNA duplex titrated into TAV2b.  
C. 21nt ssRNA titrated into TAV2b. 
D. 9nt siRNA duplex titrated into TAV2b. 
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four-helical bundle fold to bind to both siRNA duplex and long dsRNA in a length-
independent mode (Figure. 1-5 B). P19 and B2 recognize dsRNA by binding to only 
one face of the dsRNA to recognize the major or minor groove backbone (Figure. 1-5 
A and 1-5 B), whereas TAV2b recognizes dsRNA by fitting the protein backbones 
inside the major groove and wrapping around both faces of the dsRNA to recognize 
the major groove (Figure. 4-4B). Similar to FHV B2 protein, TAV2b binds to both 
siRNA duplex and longer dsRNA, although TAV2b recognizes the 5’-terminal base 
of siRNA duplex by a pair of relatively conserved tryptophan residues (Figure. 4-4B).  
The promiscuous structural and functional deviation of dsRNA recognition by 
TAV2b raises an interesting question regarding the physiological targets of TAV2b in 
host RNA silencing suppression. It is possible that both longer dsRNA and siRNA 
duplex could be the targets of TAV2b, similar to FHV B2 protein. This hypothesis is 
supported by our EMSA data (Figure. 4-1A) and the ITC data of TAV2b mutants at 
position Trp 50 (Figure. 4-5E, 4-5F and Table. 4-3), but deviates from the structural 
observation of π-stacking between Trp 50 and the 5’-terminal base and in vitro RNA 
interference suppression data (Figure. 4-4B, 4-6D, and 4-6E). Although the extensive 
protein-dsRNA contacts can compromise the slight decrease in binding affinity 
induced by mutation of Trp 50, the functional role of Trp 50 is still unclear. At 
present, we cannot rule out the possibility that Trp 50 might play a role in the 
interaction between TAV2b and the proteins involved in the silencing pathway. 
Nevertheless, Trp 50 is an invariable residue within CMV2b proteins and substituted 
by arginine in TAV2b protein (Figure. 4-3 A). The fact that arginine can also form π-
stack contact with the base of RNA suggests that the π-stack contact observed in the 




From the crystal structure, we noticed that the TAV2b dimer seems to 
accurately measure two helical turns of dsRNA by simultaneously recognizing two 
adjacent major grooves by its unique pair of hook-like structures. Our ITC analyses 
on the binding between TAV2b and different lengths of dsRNA showed that one 
TAV2b dimer recognizes two helical turns of dsRNA (N=0.5). Theoretically, this 
recognition mode can also be applied to long dsRNAs by the simultaneous binding of 
many TAV2b dimers. The weak binding affinity between TAV2b and long dsRNAs 
suggests that long dsRNAs might not be the preferred target of TAV2b [150]. The 
conserved π-stack between 2b protein at Trp 50 and dsRNA at the 5’-terminal base 
further suggests that TAV2b might prefer siRNA duplex instead of long dsRNA. In 
accordance with structural observations, ITC data show that TAV2b binds to 32 nt 
siRNA duplex (30 bp), which has three helical turns of dsRNA, with a binding 
affinity similar to that of 21 nt siRNA duplex (Figure. 4-7E and Table. 4-4).   
Previously, it was reported that CMV2b is able to target Arabidopsis AGO1 to 
suppress host RNA silencing [71]. Here, we show that TAV2b, another member of the 
cucumovirus family, is able to bind directly to siRNA duplex to repress host RNA 
silencing. Taken together, the ability of cucumovirus 2b proteins to target both the 
RNA silencing trigger (siRNA) and the slicer (Argonaute) at the same time would 
provide an enormous advantage for the virus to survive during the arms race against 






Figure 4‐8. Diagram of the RNA-silencing pathway 
Suppression of certain stages of RNA silencing by TAV2b is indicated. TAV2b is able to 
prevent siRNA incorporation into RISC by direct binding siRNA duplex and Argonautes. 
TAV2b may also be able to bind long dsRNA duplex to inhibit siRNA duplex formation.
  
 
Chapter Five: Conclusions  
RNA silencing, an antiviral mechanism can be triggered by molecular 
parasites, and consequently results in specific recognition and degradation of the 
invading viral RNAs. In response to host defense, viruses have developed widely 
varying mechanisms to conquer the host RNA-silencing, presenting a lively example 
of evolutionary competition between hosts and parasites. Along with the discovery of 
triggers (small RNAs) and engine (RISC complex) of RNA silencing pathway, the 
research on this field has been pushed forward greatly. However, we only know a tiny 
part of the molecular mechanism of either RNA silencing and the suppression of RNA 
silencing by viruses. In this thesis, our findings on the functional association between 
TRBP and kiaa1093 RRM sheds some lights on the working mechanism of RISC. 
Also the discovery of TAV2b/siRNA new binding mode provides helpful perceptive 
information to understand the diverse molecular mechanisms of RNA silencing 
suppression. 
Human Argonaute/Dicer/TRBP /bound siRNA complex, the core engine of 
RISC, has been studied extensively and thoroughly. In this complex, TRBP is 
required for the recruitment of Ago2 to the siRNA bound by Dicer. Moreover, the 
knockdown of TRBP results in destabilization of Dicer and a consequent loss of 
miRNA biogenesis. Furthermore, Dicer/TRBP complex is also required for the RISC 
assembly, whose depletion diminishes of RISC-mediated reporter gene silencing [72].  
  
 
In chapter 3, we studied another integral component, kiaa1093, in the 
Argonaute/Dicer/TRBP /kiaa1093/bound siRNA complex, the core engine of RISC, 
i.e.. 
Let us now have a closer look at the complex.   
Kiaa1093 binds with AGOs via the so called ‘AGO hook’, however so far 
there is no evidence that it has been linked to AGO function. Kiaa1093’s C-terminal 
RRM bridges the interaction with TRBP (mainly via its first domain), which is 
illuminated by affinity pull down assay. Kiaa1093 RRM is an untypical RRM that 
harbors an additional C-terminal α helix compared with typical RRMs topology 
derived from the structural information (Figure. 3-3C). It is the additional α helix that 
blocks the four-stranded anti-parallel-β sheets which is a platform for RNA 
recognition and interaction, which correspondingly compromises kiaa1093 RRM 
RNA binding capacity. However, it is also the additional α helix that is critical to 
bridge the interaction between Kiaa1093 RRM and TRBP. 
TRBP alone has very weak binding affinity with siRNA (Figure. 3-8A) [72]. 
Interestingly, TRBP’s RNA binding affinity is greatly enhanced, when it is together 
with Dicer [72].  However TRBP’s RNA binding affinity changes little when it is 
along with kiaa1093 RRM (Figure. 3-8B, C, and D), whereas TRBP D1+2’s binds to 
RNA with much higher affinity at the present of kiaa1093 RRM (Figure. 3-8D and E). 
 These phenomenons might result from the following plausible reasons. We 
have known that the second domain (D2) mainly harbors RNA binding capacity. It is 
possible that D1 and/or D3 interfere with D2 / RNA interaction in free form TRBP. 
TRBP D3 is interacting with Dicer helicase, whereas TRBP D1 binds to kiaa1093 
  
 
RRM. The association of Dicer helicase and/or kiaa1093 RRM changes TRBP 
conformation, and correspondingly exposes the RNA binding domain in D2.  
Therefore TRBP shows higher RNA binding affinity at the presents of TRBP’s 
binding partners.  
Considering that it is D1+2 but not full length TRBP has enhanced RNA 
binding affinity at the present of kiaa1093 RRM, it is reasonable to hypothesize that 
the interaction between D3 and Dicer helicase together with interaction between D1 
and kiaa1093 might completely activate the conformation change of TRBP, and 
sequentially strengthens the TRBP/siRNA complex. Therefore, it is possible that 
kiaa1093 might serve as a scaffold protein to strengthen Argonaute/Dicer/TRBP 
/bound siRNA supercomplex. Kiaa1093 binds with TRBP via the bridge between C-
terminal RRM domain and TRBP D1 to stabilize the TRBP/siRNA interaction to 
facilitate the production of siRNA with Dicer. On the other hand, kiaa1093 interacts 
with AGOs to assist the small RNAs loading into AGOs. 
However, we only establish the interaction between kiaa1093 RRM and TRBP 
in vitro, and lack of in vivo evidence. In future, we plan to perform in vivo 
experiments to support our conclusions.  
In chapter 4, we report the complex crystal structure of TAV2b bound to a 21 
siRNA duplex, which thoroughly elucidates 2b's possible strategy to suppress RNA 
silencing by targeting dsRNA.  
Viruses encode a wide range of suppressors with various sequences, motifs 
and structures to counter host defense by targeting different steps of RNA silencing 
pathway via different strategies. On the basis of the current studies, there are mainly 
  
 
two strategies displayed by viral suppressors. One is targeting small RNAs, the other 
is to interfere with protein components in RNA silencing pathway (detailed discussion 
in chapter 1). Interestingly, even in the same group, the suppression mechanisms vary 
greatly by different suppressors.  
Although its homolog CMV 2b is targeting AGO1 in Arabidopsis, TAV2b is a 
RNA binding protein. Compared with the previous reports of suppressor/RNA 
complex, (either TBSV p19 which sequesters siRNA in sequence-depending mode, or 
FHV B2 which adopts sequence-independing mode), TAV2b adopts a novel binding 
mode: an all α-helix structure and forms a homodimer to measure siRNA duplex in a 
length-preference mode.   
Although dimerized TAV2b also contains a pair of Trp residues projecting 
from each C-terminal α2 helix to recognize both ends of siRNA, the measurement of 
TAV2b is different from that of TBSV p19. p19 forms a head to tail homodimer 
arrangement and there are two sets of tryptophan residues projected form its ‘read 
head’ α helix to stack over the 5’-end bases of siRNA duplex, leading to effective 
measurement of the duplex length [104, 111]. TAV2b recognize and interact with 
siRNA by measuring the width of the major groove of siRNA duplex. Compared to 
DNAs which general adopt B-form (10.5 bp per turn), most of RNAs adopt A form, a 
wider right-handed spiral (general 11bp per turn). Derived from the structural 
information, TAV2b distinguishes dsRNAs by fitting its α-helical backbone into the 
major groove (Figure. 4-2). Therefore TAV2b has very low binding affinity with 7bp 
dsRNA and 21ssRNA, which does not form complete major grooves. And TAV2b has 
lower binding affinity with dsDNA (B-form) and 12nt small RNA (hardly to form a 
  
 
complete turn) (Figure.4-7 and Table 4-4). Thus the measurement by TAV2b is not 
strictly despite of the two Trps projecting from both sides of the structure. The 
promiscuous structural and functional deviation of dsRNA binding by TAV2b 
suggests that both longer dsRNA and siRNA duplex might be the targets of TAV2b, 
which is similar to FHV B2 protein.  
We also characterize the key residues of TAV2b involved in either protein-
protein or protein-RNA interaction. The complex structure indicates that dimerized 
TAV2b further forms a tetramer through the conserved leucine-zipper-like motif at 
the N-terminal α helix (Figure 4-5B, and Table 4-2). The mutations of leucine-zipper-
like motif disrupt suppression of silencing of TAV2b (Figure. 4-6).  
Another key residue is Try 50 which has been mentioned above. Although the 
pair of Trp (50) residues are not an efficient ruler for measuring the length of the 
bound RNA and the mutations of Trp 50 only compromise slight decrease in RNA 
binding affinity (Figure. 4-5E, F, and Table. 4-3), the mutations of Trp 50 greatly 
diminish the suppression of silencing by TAV2b (Figure. 4-6). It is possible that Trp 
50 plays a role in the interaction between TAV2b and the proteins involved in the 
silencing pathway.  
TAV2b also encodes a putative NLS at the N-terminal half of the protein. 
Moreover, similar to CMV 2b, transient expression of TAV2b is targeted in nuclei. It 
was reported that CMV 2b is localized in the nuclei of tobacco suspension cells and 
whole plant via an arginine-rich NLS and the nuclear targeting of the CMV 2b is 
required for the efficient suppression of PTGS [146]. Thus it is possible that NLS 
encoded by TAV2b is also important for suppression of PTGS. In our report, the 
  
 
mutations of Arg 28 and the invariable His 29, which are the residues in TAV2b NLS, 
decrease the RNA the RNA binding affinity by ten times, and are defective in 
silencing suppression of TAV2b in vitro. It would therefore appear that 2b proteins 
encoded by the cucumovirus are likely to be targeted to the nuclei of the invaded cells 
and PTGS may be blocked in nucleus. 
Previously, we have discussed there are mainly two kinds of suppressors on 
the basis of the current reports; one is targeted at RNA whereas the other is targeted at 
protein effectors in RNA silencing pathway. Interestingly, CMV2b is able to target 
Arabidopsis AGO1 to suppress host RNA silencing, whereas, TAV2b, another 
member of the cucumovirus family, is able to bind directly to siRNA duplex to 
repress host defense. Taken together, cucumovirus 2b proteins targets both the 
triggers and the silencers in RNA silencing pathway, which provides an enormous 
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